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 Despite available treatment options, the number of people afflicted by type 
2 diabetes has steadily risen for decades. Nearly 90% of the diabetic population 
also suffers from obesity and the link between the two diseases is undeniable. 
Characterized by rapid expansion of the adipose tissue and improper lipid storage, 
the mishandling of lipids by adipose tissue promotes the diabetic state. Excess 
lipids, unable to be properly stored, build up in peripheral tissues promoting insulin 
resistance and type 2 diabetes. Therapeutic strategies designed to address 
adipose tissue lipid handling could represent a promising treatment strategy for 
obesity associated type 2 diabetes. Here we investigate the use of polymer 
scaffolds made of poly(lactide-co-glycolide) as a way to engineer adipose tissue 
lipid metabolism. Implant of scaffolds into the epididymal adipose tissue of mice 
leads to glucose and lipid utilization and is attributed to the host response to the 
material. This lipid oxidizing effect is enhanced by incorporating resveratrol into the 
polymer scaffolds. Importantly, implant of scaffolds protects mice against fat gain 
and insulin resistance in a mouse model of obesity associated type 2 diabetes. 
Finally, we demonstrate the ability of scaffolds combined with healthy dietary 
changes to reverse insulin resistance in a mouse model of obesity associated type 
2 diabetes. Taken together, this work demonstrates promise for tissue engineering 
strategies designed to address adipose tissue lipid handling as a platform to treat 
obesity associated type 2 diabetes.  
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1.1. Defining obesity and its underlying causes.  
Clinically obesity is defined as an adult with a body mass index (BMI), an 
estimate of body fat content based on the height and mass of the individual, over 
301. Obesity is the result of an energy imbalance where caloric intake exceeds 
caloric expenditure. The body responds to excess energy intake by storing surplus 
calories in the form of lipids (fat) in the adipose tissue (fat tissue)2.  The excess 
lipid storage, results in the rapid expansion of the adipose tissue, progressing in 
severity until the individual’s fat mass has expanded to a point where a clinical 
diagnosis of obesity is given.  
1.2. The obesity epidemic and its health and economic burden. 
The National Institutes of Health and the Center for Disease Control 
estimate that 32.7% of adults in the United States are overweight and 37.9% are 
obese as of 20141. These rates have continued to climb throughout the decades, 
and it has been projected that half of all U.S. adults will be obese by 20303. 
Importantly, obesity is associated with increased incidents of type 2 diabetes, 
cardiovascular disease, stroke, dyslipidemia, and certain cancers4. The 
comorbidities associated with obesity place a substantial burden on the quality of 
life of individuals affected with these conditions. In addition to diminished quality of 
life, obesity also has a large economic burden. The healthcare costs for obese 
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individuals has been estimated to be 30% higher than those with normal weight3. 
The elevated cost of healthcare combined with the increased prevalence of obesity 
resulted in estimates that obesity related healthcare accounted for 27% of the 
growth in U.S. healthcare spending from 1987-20013. This rate of spending is 
expected to double every decade, rising with the ever increasing population of 
obese individuals, with estimates that obesity and its related complications will 
account for 16-18% of total U.S. health care expenditure by 20305. Taken together, 
the overwhelming prevalence and burdens, both health and economic, associated 
with obesity highlight the dire need to understand more about the condition and 
develop new and innovative platforms for its treatment.  
1.3. Adipose tissue biology. 
The tissue most directly associated with obesity is the adipose tissue, or fat 
tissue. For decades the adipose tissue was considered to be an inert tissue whose 
only function was to store excess caloric energy in the form of lipids. However, 
research over the past decade has revealed a much larger role for the tissue in 
whole body metabolism. In addition to the tissue’s storage capabilities, the adipose 
tissue functions as an endocrine organ, secreting a variety of hormones, cytokines, 
and other factors which function to regulate glucose and lipid metabolism both 
locally and in distant tissues6. Examples of important hormones secreted by the 
adipose tissue include adiponectin, a hormone which functions to stimulate 
glucose uptake and lipid metabolism in distant tissues such as the skeletal muscle7 
and leptin, which signals in the hypothalamus to induce satiety8. In addition, levels 
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of lipids and fatty acids released from the adipose tissue can also signal in distant 
tissues in a similar manner to the hormones described above.  
These endocrine functions of the adipose tissue are regulated not just by 
the adipocytes (fat cells), the most prevalent cell population in the tissue, but also 
the local immune cells that reside within the tissue9. Specifically, adipose tissue 
macrophages, the second most prevalent cell population in the adipose tissue, 
play a large role in regulating the tissue’s endocrine functions. In healthy adipose 
tissue, macrophages express an anti-inflammatory gene profile and have various 
functions including efferocytosis (removal of dying or dead cells), lipid buffering, 
and angiogenesis9. The importance of healthy interaction between adipocytes and 
adipose tissue macrophages is highlighted when it becomes dysregulated in the 
obese state, explained further in the subsequent section.   
1.4. The link between obesity and type 2 diabetes. 
Out of all comorbidities associated with obesity, the link between obesity 
and type 2 diabetes is clearly established. Over 90% of type 2 diabetics also suffer 
from obesity10. There is no question that adipose tissue dysfunction constitutes a 
mechanistic link between obesity and diabetes11. Healthy adipose tissue serves 
as an energy reservoir that expands during overnutrition to store excess calories 
as lipids and releases these lipids in response to an energy deficit6. In the obese 
state, adipose tissue has a limited capacity to store additional lipids, and this is 
especially evident in adipose tissue around internal organs (visceral fat)12. The 
excess lipid in the visceral fat causes inflammation, which leads to the influx of 
inflammatory macrophages. Lipids are then secreted from the dysfunctional 
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visceral fat and accumulate in the liver and muscle, known as ectopic lipid 
deposition, where they cause insulin resistance and inflammation13–15. 
Concurrently, there is a decline in the release of hormones that promote insulin 
sensitivity, glucose uptake, and lipid catabolism in peripheral tissues16. This 
constellation of maladaptation leads to hyperglycemia, which damages the 
cardiovascular system and other vital organs, including the pancreas17,18 which 
over time leads to the onset of type 2 diabetes.  
1.5. Current treatment strategies and shortcomings.  
The first line of defense when treating obesity associated type 2 diabetes 
focuses on lifestyle changes such as diet and exercise. However, many patients 
fail to strictly adhere to these lifestyle changes. Reasons for non-compliance are 
multifactorial, some of the more commonly cited complaints from patients include 
a lack of motivation, failure to see noticeable progress, and the inability to adhere 
to therapies due to a physical injury19. Due to these reasons, the success of 
lifestyle changes in treating obesity associated type 2 diabetes has been estimated 
to be as low as 10%20.  
When lifestyle changes fail to achieve adequate glycemic control, 
treatments are often supplemented with pharmacological agents designed to lower 
blood glucose levels. These pharmacological agents lower blood glucose in a 
variety of ways such as lowering hepatic glucose production (metformin)21, 
increasing renal excretion of glucose (canagliflozin)22, and stimulating the 
pancreas to secrete additional insulin (glipizide)23, however these strategies fail to 
address the underlying adipose tissue dysfunction behind the disease. 
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Furthermore, it has been estimated that over 50% of patients on current treatment 
regimens fail to achieve their glycemic goals which has been attributed to issues 
such as poor patient compliance, low bioavailability, and unintended off target 
effects cause by systemic administration of pharmacological agents20. Therefore, 
novel therapeutic strategies specifically designed to improve adipose tissue health 
and storage capacity while addressing the drawbacks of existing therapies could 
have a greater chance of success when translated to the clinical setting. 
1.6. Biomaterial scaffolds for tissue engineering.  
Tissue engineering is a strategy that combines life sciences with 
engineering principles to restore or direct tissue function24,25. Biomaterials are 
commonly employed in these techniques as delivery vehicles of therapeutic agents 
such as cells, proteins, and small molecules. Poly(lactide-co-glycolide) or PLG is 
one of the most popular biomaterials for tissue engineering applications as it is 
tolerated well by the body and has gained FDA approval for various therapeutic 
applications such as VivitrolÒ, which delivers naltrexone from PLG microparticles 
to treat alcoholism and ZoladexÒ, a solid implant of PLG that delivers goserelin 
acetate to treat prostate cancer26,27. In the field of tissue engineering, scaffolds 
made of PLG have been studied for a wide variety of applications such as bone 
regeneration28,29, delivery of islet cells to treat type 1 diabetes30, and modulating 
the foreign body response to materials31. However, while PLG scaffolds have been 
implanted into the adipose tissue in previous studies30,32, their effects on the 
adipose tissue have been left uncharacterized. Therefore, the focus of the 
research in this dissertation was to assess the ability of PLG scaffolds to engineer 
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the lipid metabolism in the adipose tissue as a therapeutic strategy to treat obesity 
associated type 2 diabetes.  
1.7. Design of polymer scaffolds for the correction of obesity associated 
adipose tissue dysfunction. 
The central hypothesis of this dissertation is that biomaterial scaffolds 
implanted into the adipose tissue can be used to increase lipid metabolism in the 
tissue, thereby preventing ectopic lipid deposition in peripheral tissues which 
drives insulin resistance, providing a novel platform for the treatment of obesity 
associated type 2 diabetes. The proposed project will test this hypothesis with a 
set of three specific aims designed to (1) demonstrate the efficacy of a polymer 
scaffold-based therapy at treating impaired insulin resistance in obesity associated 
type 2 diabetes as well as (2) allow understanding of the mechanism of action 
behind this approach and (3) understand how this treatment method combines with 
healthy lifestyle changes. Anticipated results would establish scaffold-based 
therapies as a viable platform for the treatment of obesity associated type 2 
diabetes and establish a foundation on which future studies could build off of, 
eventually leading to a clinically translatable therapy.  
1.7.1 Aim 1: Characterize the effects of poly(lactide-co-glycolide) scaffolds on 
adipose tissue function. 
In order to gain an understanding of how tissue engineering scaffolds alone 
impact adipose tissue function, initial studies were completed on unloaded polymer 
scaffolds. Scaffolds used in Aim 1 were composed of poly(lactide-co-glycolide). 
This polymer was selected for pilot studies as it has been implanted into the 
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adipose tissue for various pre-clinical applications30,32,33.  Polymer scaffolds were 
implanted into the epididymal adipose tissue of male C57BL/6 mice. Important 
read outs were levels of glucose transport proteins both at the implant site and in 
distant tissues, as well as local and systemic levels of health promoting hormones, 
specifically adiponectin, leptin, insulin, and insulin-like growth factor 1 (IGF-1). 
Finally, clinical translatability was assessed using the high fat diet mouse model, 
a common pre-clinical model of obesity associated type 2 diabetes. Anticipated 
results will provide an understanding of the changes in glucose transport and 
adipose tissue function caused by unloaded scaffolds, allowing for the 
incorporation of additional agents (e.g. drugs, cells, proteins) to further augment 
the therapeutic effects cause by the polymer.  
1.7.2 Aim 2: Incorporate resveratrol into polymer matrix for direct delivery to the 
adipose tissue in order to promote lipid metabolism.  
 In order to demonstrate the efficacy of PLG scaffolds as drug delivery 
vehicles to the adipose tissue, the naturally occurring polyphenol resveratrol was 
incorporated into the matrix of the scaffolds. Resveratrol was selected for this study 
as it has shown to have beneficial effects on the adipose tissue including promoting 
the oxidation of lipids and fatty acids for fuel34, however it requires high oral 
dosages due to its rapid metabolism in the bloodstream35. Direct delivery of 
resveratrol to the adipose tissue from PLG scaffolds could improve the 
bioavailability of the drug. Similar to Aim 1, experimental read outs were local and 
systemic measurements of glucose transport and fat accumulation. Clinical 
translation was determined using a high fat diet mouse model of obesity associated 
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type 2 diabetes. Anticipated results from this aim demonstrate the therapeutic 
efficacy of drug delivery to the adipose tissue from polymer scaffolds. Additionally, 
the successful incorporation of resveratrol into the polymer matrix provides a 
platform which can be easily translated to other small molecules with 
physiochemical properties similar to that of resveratrol. 
1.7.3 Aim 3: Assess of the ability of resveratrol loaded scaffolds to combine with 
healthy dietary changes. 
Often times in the treatment of obesity, pharmacological therapies are 
combined with lifestyle changes such as improved diet and exercise. Therefore, 
the ability of resveratrol loaded scaffolds to combine with changes in healthy diet 
changes and promote healthy adipose tissue function and glucose uptake is 
important to understand. To this end, mice were placed on the high fat diet mouse 
model prior to administration of resveratrol loaded scaffolds to induce fat gain and 
glucose intolerance. Resveratrol loaded scaffolds were then implanted into the 
adipose tissue and the mice were returned to a normal diet simulating a healthy 
dietary change. Readouts from this study were weight reduction and glucose 
intolerance which was assessed as the mice returned from the diseased to healthy 
state.    
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CHAPTER 2 
THE HOST RESPONSE TO POLY(LACTIDE-CO-GLYCOLIDE) 
SCAFFOLDS PROTECTS MICE AGAINST DIET INDUCED 
OBESITY AND GLUCOSE INTOLERANCE 
2.1  Introduction. 
The adipose tissue plays an important role in energy homeostasis by storing 
excess glucose and dietary lipids as triglycerides and secreting endocrine acting 
factors (adipokines) that modulate glucose and lipid metabolism6. Indeed, the 
importance of proper adipose tissue function is emphasized by the adverse 
metabolic consequences of both its excess (obesity) and its deficiency 
(lipodystrophy). In both cases lipids circulate at high levels in the blood stream and 
accumulate at undesirable sites, such as muscle and the liver, causing insulin 
resistance13–15. Furthermore, there is a decrease in production of health promoting 
adipokines16. This constellation of maladaptation impairs glucose tolerance and 
causes hyperglycemia, which damages the cardiovascular system and other vital 
organs, including the pancreas17,18. The first line of defense, in concert with diet 
and exercise, is antidiabetic medications that improve insulin sensitivity or promote 
insulin production; however, their side effects hinder drug safety, patient 
compliance, and drug effectiveness20. 
Rather than treating hyperglycemia with systemic drug administration, a 
more pragmatic approach might be to engineer the adipose tissue to improve its 
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storage of glucose and lipids or augment its production of adipokines that naturally 
promote their metabolism. Polymeric scaffolds are a promising platform to 
accomplish these goals as they can be designed to release bioactive factors that 
modulate these functions. In this work we investigated porous poly(lactide-co-
glycolide) (PLG) scaffolds (Fig. 2.1) for drug delivery to the epididymal adipose 
tissue of mice. PLG was selected for its established track record as a drug delivery 
matrix in several FDA approved devices26,36 and previous work indicating that 
porous PLG scaffolds integrate well with the epididymal fat31,32. To our surprise, 
we detected a decrease in fasting blood glucose levels in healthy mice that 
received PLG scaffolds with no drug payload. In addition, epididymal fat pads with 
scaffold implants were significantly smaller compared to controls. Intrigued, we set 
out to determine how “empty” scaffolds might modulate blood glucose levels and 
fat pad size and if these responses had therapeutic implications. Guiding these 
studies was the overarching hypothesis that the increased cellular activity that 
occurs during scaffold integration with the host tissue (i.e. the host response) was 
 
Figure 2.1. PLG scaffolds for implant into adipose tissue. (A) Photograph of 
scaffold relative to a United States penny. Scanning electron microscope images of a 
(B) side and (C) top profile of a scaffold. Scaffolds are 5 mm in diameter, 2 mm in 
height, and 98% porous with a pore size ranging between 250 and 500 microns. 
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associated with increased expression of proteins that promote glucose uptake and 
that this response was sufficient to mitigate glucose intolerance induced by a high 
fat diet. 
2.2  Methods. 
Scaffold Fabrication.  
Poly(lactide-co-glycolide) (PLG) microspheres were prepared as previously 
described37. Briefly, PLG (75:25 mol ratio d,l-lactide to glycolide, 0.76 dL/g) 
(Evonik) was dissolved in dichloromethane to make a 6% (w/w) solution, which 
was then emulsified in 1% poly(vinyl alcohol) to create microspheres. The 
microspheres were collected by centrifugation, washed with deionized water, and 
lyophilized overnight. Microspheres were combined in a 1:30 mass ratio with NaCl 
particles 250–500 µm in diameter. The mixture was pressed in a steel die at 1000 
pounds per square inch (psi) and gas-foamed using 800 psi CO2 gas at room 
temperature. The salt porogen was removed by washing in deionized water. 
Complete salt removal was confirmed by scaffold weight and microscopy. Prior to 
implantation, scaffolds were washed in 70% ethanol and rinsed in sterile 
phosphate buffered saline (PBS; Life Technologies).  
Scanning Electron Microscopy and Histology. 
Scanning electron microscopy was performed using standard techniques. 
Briefly, scaffolds were placed on aluminum SEM stubs coated with carbon 
adhesive tape. Scaffolds were then sputtered with gold for 1 minute 3 times to 
ensure complete coating. Images were taken on a TESCAN Vega3 scanning 
electron microscope at 10kV. For histology, epididymal fat pads were excised, 
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fixed in 4% paraformaldehyde for 24 hours, and embedded into paraffin blocks. 7 
µm sections were cut from each block and stained with hematoxylin and eosin 
(H&E). Analysis of adipocyte size was performed using Image J’s MRI Adipocyte 
tool. 
Animals. 
Male C57BL/6J mice were purchased from Jackson Laboratory at 6 weeks 
of age. All animals were housed with ad libitum access to water and food in a 
temperature-controlled room with a 12:12 h light:dark. All procedures were 
performed in accordance with NIH Guidelines for Care and Use of Animals and 
were approved by the Institutional Animal Care and Use Committee at the 
University of South Carolina. Mice were allowed to acclimate for two weeks prior 
to study. 
Scaffold Implantation.  
Mice received scaffold implant into the epididymal fat as previously 
described. Briefly, mice were anesthetized with a 2% mixture of isoflurane and 
oxygen (2 L/min), and the abdominal midline was shaved and prepped in a sterile 
fashion. Following a lower abdominal midline incision, scaffolds were wrapped in 
each epididymal fat pad. The abdominal wall was then closed with a running stitch, 
and the skin was closed with wound clips. Lean animals received one scaffold per 
fat pad. Mice challenged with high fat diet received two scaffolds per fat pad. 
Food Intake Measurements.  
Food was weighed at the beginning and end of each week and the total 
grams of food consumed was calculated. To obtain kcal per mouse, weight of food 
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consumed was normalized by the number of mice in the cage and multiplied by 
the calorie density in the food (3 kcal/gram).  
Enzyme-Linked Immunosorbent Assays (ELISA). 
Blood was collected from mice fasted for 6 hours retro-orbitally into EDTA 
coated tubes, spun down at 10,000 g, and plasma was isolated. Adipose tissue 
was homogenized in RIPA buffer (Thermo Scientific) supplemented with protease 
inhibitor cocktail (Thermo Scientific), phospho-stop (Roche), and phenylmethane 
sulfonyl fluoride (Sigma). Following homogenization, protein was isolated via 
centrifugation at 18,000 g for 45 minutes. ELISA was used to determine mg of 
analyte per mg of adipose tissue; results were then normalized to naïve controls. 
Insulin ELISA kit was purchased from ALPCO. All other ELISA kits were purchased 
from R & D Systems.  
Immunoblotting.  
Both adipose tissue and gastrocnemius protein was isolated as described 
in the section above. Protein concentrations were determined using a BCA assay 
(Thermo Scientific). Lysates (30 ug adipose tissue, 100 ug gastrocnemius) were 
separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Proteins 
were then transferred to a nitrocellulose membrane (GE Healthcare Life Sciences) 
and incubated with appropriate antibodies. Secondary antibody was a horseradish 
peroxidase (HRP)-conjugated anti-rabbit immunoglobulin G (IgG) grown in goat 
(Abcam). Proteins were then visualized using SuperSignal West Pico substrate 
(Thermo Scientific). Antibodies to Glut1, total Akt, phospho-Akt ser 473, and 
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GAPDH were purchased from Cell Signaling Technology (1:1000 dilution). The 
antibody for Glut4 was purchased from Sigma Aldrich (1:1000 dilution). 
Clodronate Liposome Injections. 
Clodronate liposomes (Liposoma B.V.) were injected into the intraperitoneal 
cavity. 100 uL was administered at a concentration of 5 mg/mL. Liposomes were 
warmed to room temperature and mixed thoroughly before injection. After 48 
hours, mice received scaffold implants as described above. A control group of mice 
also received the scaffold implant without an injection of clodronate liposomes. 
Flow Cytometry. 
Following euthanasia, epididymal fat pads were excised and washed in ice 
cold PBS. Fat pads were shredded, digested in collagenase (Liberase TL, Roche), 
and passed through a 100 µm filter to remove debris. The stromal vascular fraction 
was separated by centrifugation and washed in MACS buffer (PBS, 0.5 mM EDTA, 
30% BSA). Before applying antibody panels, samples were incubated with an anti-
CD16/32 antibody to reduce nonspecific binding. After antibody incubation, 
samples were washed in MACS buffer, fixed, and analyzed using a FACS Aria flow 
cytometer (BD Biosciences). Total number of macrophages (F4/80+ CD11b+ cells) 
in each sample was calculated by adding Bang’s labs Flow Cytometry Absolute 
Count Standard, prior to data acquisition. Compensation and data analysis were 
completed using FlowJo software (Treestar). FMOs with isotype controls were 
used to determine specific antibody signal. The gating scheme used in the flow 
cytometry analysis is outlined in Supplemental Figure 2.10. 
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High Fat Diet Feeding. 
After two weeks of acclimation, mice were placed on a 60% high fat diet 
(Research Diets D12492) while a control group was kept on a normal diet (Teklad 
8904). On caloric basis, the high-fat diet consisted of 60% fat from lard, 20% 
carbohydrate, and 20% protein (total 5.24 kcal/g), whereas the normal diet 
contained 12% fat, 66% carbohydrate, and 22% protein (total 3.0 kcal/g). Mice 
were kept on the high fat diet for one week prior to scaffold implantation and 
remained on the diet for the remainder of the experiment. 
Duel-Energy X-ray Absorptiometry (DEXA). 
Body composition was assessed using DEXA scans (Lunar PIXImus). Each 
mouse was anesthetized for the duration of the procedure (5 min) by exposure to 
2% isoflurane-oxygen gas via nose cone. Each mouse was placed on the scanner 
bed in the prone position, with the limbs and tail stretched away from the body. 
One scan per mouse was performed and analyzed with PIXImus software (Lunar). 
The head was excluded from calculation using a manual ROI. The PIXImus was 
calibrated with an aluminum/Lucite phantom (corresponding to bone mineral 
density = 0.0592 g/cm2 and 12.5% fat) on each day of testing according to the 
manufacturer's instructions. 
Intraperitoneal Glucose Tolerance Test (IPGTT).  
Mice were fasted for 6-hours before receiving injections of D-glucose into 
the intraperitoneal cavity. Glucose administered was normalized to the lean mass 
calculated via a DEXA scan that was conducted one-day prior (2 g glucose per kg 
lean mass). Blood samples were collected via a tail vein prick at 0, 15, 30, 60, 90, 
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and 120 minutes after glucose administration. Glucose measurements were 
obtained using a handheld glucose meter (Accu-Chek Nano, SmartView). 
In-vivo glucose uptake assay. 
 Mice were implanted with one scaffold into either the left or right epididymal 
fat pad. The contralateral fat pad served as an internal control. In addition, naïve 
mice were included in the experiment for comparison. The glucose uptake assay 
was performed two weeks after scaffold implant. Mice were fasted 6 hours prior to 
the start of the experiment. 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-
deoxyglucose (2-nbdg) (Cayman Chemical) was reconstituted in sterile PBS at a 
concentration of 10 mg/mL. Each mouse received 100 mg/kg of 2-nbdg via an 
intraperitoneal injection. After two hours, tissues were harvested and washed 
thoroughly in PBS before imaging on an IVIS Lumina III at 480/570 nm 
(excitation/emission). Manual ROIs were drawn around each tissue. The 
measurements are presented as the total radiant efficiency from a tissue 
normalized by that tissue’s weight. 
Statistical Analysis. 
Data are plotted as mean ± standard deviation. Statistical analyses were 
conducted using GraphPad Prism version 7. P values less than 0.05 were 
considered significant. Two groups were compared using an unpaired two tailed t-
test. Groups of three or more were compared using a one-way ANOVA with 
Tukey’s multiple comparison test. Two or more groups over time were compared 
by two-way ANOVA with Tukey’s multiple comparisons test. 
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2.3  Results. 
Implant of PLG scaffolds into the epididymal adipose tissue lowers fasting blood 
glucose. 
A hallmark of a promising diabetes therapy is its ability to lower blood 
glucose levels. We found that PLG scaffolds caused a significant decrease in 
 
Figure 2.2. Impact of scaffold implant on C57BL/6 mice. (A) Fasting blood glucose 
measured 2 weeks after implant. Sham controls received implant procedure, but no 
scaffold. (B-E) Plasma insulin, adiponectin, leptin, and IGF-1 measured 2 weeks after 
implant. (F) Percent change in body weight from the day of scaffold implant over time. 
(G) Weekly kcal intake per mouse over the 2-week experiment. (H) Intraperitoneal 
glucose tolerance test completed 2 weeks after implant and (I) area under the curves. 
Statistics calculated using a one-way ANOVA with Tukey’s multiple comparison test. * 
indicates p<0.05 versus naïve, † indicates p<0.05 versus sham. n=3-5 mice per 
condition. 
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fasting blood glucose when implanted into the epididymal fat of C57BL/6 mice (Fig. 
2.2A). The drop in fasting glucose occurred without significant changes in plasma 
insulin (Fig. 2.2B), adiponectin (Fig. 2.2C), leptin (Fig. 2.2D), or IGF-1 levels (Fig. 
2.2E), which are hormones that promote glucose uptake38–41. The implant 
procedure alone (sham), which is a major surgery, also lowered fasting blood 
glucose; however, the scaffold group’s blood glucose was significantly lower 
compared to the sham group. The surgery also led to fluctuations in weight gain 
(Fig. 2.2F) and an increase in food intake (Fig. 2.2G) compared to age and sex 
matched mice that were unmanipulated (naïve), but we did not detect significant 
differences in weight or food intake between the sham and scaffold groups. We 
suspect increased food consumption was due to increased energy requirements 
to recover from the surgery42. The decreased fasting blood glucose led us to 
investigate if whole-body glucose tolerance was affected, but we did not detect a 
difference in the area under the curve between any of the groups following an 
intraperitoneal glucose tolerance test (Fig. 2.2H-I). Taken together, these results 
indicate that scaffold implant lowers fasting blood glucose levels and suggests this 
effect is not due to changes in the plasma levels of hormones that promote glucose 
uptake.  
Scaffolds promote elevated glucose uptake at the implant site. 
 Mice with scaffolds exhibited lower fasting blood glucose levels than naïve 
mice (Fig. 2.2A). Thus, we investigated in fasted mice how scaffolds impact 
glucose uptake at the implant site (epididymal fat) and in other tissues. To 
accomplish this, we fasted mice for 6 hours and then injected them 
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intraperitoneally with 2-nbdg, which is a fluorescent tracer for measuring glucose 
uptake in tissues43. Two hours after 2-nbdg injection, tissues were harvested for 
analysis. Fluorescent images of these tissues are shown in Fig. 2.3A. The top 
Figure 2.3. Effect of scaffold implant on glucose uptake in tissues from fasted 
mice. (A) Fluorescent images of tissues that are sites of glucose uptake. iWAT and 
eWAT indicate epididymal and inguinal fat pad, respectively. The top panel is 
representative of naïve (unmanipulated) mice. The bottom panel is representative of 
mice implanted with a scaffold into an epididymal fat pad 2 weeks prior to the 
experiment. The contralateral epididymal fat pad was not manipulated. Mice were 
fasted for 6 hours and then injected with 2-nbdg, a fluorescent glucose analogue. 
Tissues were harvested two hours later. (B) Quantification of fluorescent signal, which 
is indicative of glucose uptake, detected in epididymal fat pads. Statistics calculated 
using a one-way ANOVA with Tukey’s multiple comparisons test. * indicates p<0.05 
compared to naïve, † indicates p<0.05 compared to contralateral. (C) Quantification of 
fluorescent signal in the other tissues from panel A. Statistics calculated using an 
unpaired t-test. No differences were detected. n=3 mice for naïve and n=6 mice for 
scaffold. 
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panel is representative of a naïve mouse and the bottom panel is representative 
of a mouse that received one scaffold into an epididymal fat pad 2 weeks before 
the experiment. The contralateral epididymal fat pad was not manipulated. 
Strikingly, glucose uptake is most apparent in the immediate vicinity of the scaffold 
in epididymal fat (white dotted circle in Fig. 2.3A). Quantitatively, glucose uptake 
was increased by 60% in epididymal fat pads with a scaffold compared to the 
contralateral control or epididymal fat from naïve mice (Fig. 2.3B). Glucose uptake 
was unchanged for all other tissues investigated; however, we did note that all 
tissues from the scaffold group tended to have higher glucose uptake compared 
to the naïve group except for the spleen (Fig 2.3C). Taken together, the data 
suggest that the decrease in fasting blood glucose in mice with scaffolds is due to 
enhanced glucose uptake at the scaffold implant site. 
Scaffold implant modulates expression of proteins that regulate glucose uptake 
within the adipose tissue. 
The results of the in vivo glucose uptake assay encouraged us to investigate 
molecular mechanisms behind enhanced glucose uptake at the implant site; 
therefore, we investigated expression of Glut1 and Glut4, glucose transporters that 
can modulate blood glucose levels44,45. Glut4 expression was unchanged in the 
epididymal adipose tissue of mice with scaffolds (Fig. 2.4C); however, Glut1 
expression was increased threefold (Fig. 2.4B). Glut1 resides on the plasma 
membrane of many cell types and is responsible for basal glucose uptake46–48. In 
contrast, Glut4 modulates blood glucose levels by translocating from intracellular 
stores to the plasma membrane following signaling through the insulin/IGF-1 
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pathway. This translocation is maximally facilitated through Akt phosphorylation at 
serine 47349,50. Surprisingly, we found that Akt phosphorylation at serine 473 was 
significantly decreased in fat pads with scaffold implants (Fig. 2.4D), suggesting 
Glut4 may not be involved in lowering fasting blood glucose levels two weeks after 
scaffold implant. To investigate if other tissues distant from the implant site 
exhibited changes in glucose transporters or Akt signaling, we repeated our 
analysis in the gastrocnemius (Fig. 2.4E-H). Congruent with our findings from the 
in vivo glucose uptake assay, which indicated that glucose uptake was unchanged 
in the gastrocnemius of mice with scaffold implants, we did not observe differences 
in Glut1, Glut4, or pAkt levels between the scaffold and sham groups. 
Figure 2.4. Effect of scaffold implant on glucose transporters and Akt signaling 
in the epididymal fat and gastrocnemius. Representative western blots and their 
quantification for Glut1, Glut4, phosphorylated Akt (s473), and total Akt in the (A-D) 
epididymal fat and (E-H) gastrocnemius 2 weeks after implant. Data normalized to 
naïve controls. Statistics calculated using an unpaired t-test. * indicates p<0.05 versus 
sham. n=3-5 mice per condition. N = naïve, Sh = Sham, Sc = Scaffold. 
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We next sought to determine possible causes for the decreased levels of 
phosphorylated Akt in the epididymal fat implanted with scaffolds. Chronic insulin 
or IGF-1 receptor signaling can decrease Akt phosphorylation51 and thus we 
investigated expression of insulin and IGF-1 in the tissue. While we did not find 
differences in insulin levels in the epididymal fat (Fig. 2.5A), IGF-1 expression was 
elevated as early as seven days after scaffold implant and remained elevated 
after 28 days (Fig. 2.5B). In contrast, adiponectin and leptin levels were not 
different between the scaffold and sham groups (Fig. 2.5A). These data indicate 
that scaffold implant into the epididymal fat increases Glut1 and IGF-1 expression 
and suggest that local glucose uptake through their elevated expression leads to 
decreased blood glucose levels. 
 
 
Figure 2.5. Effect of scaffold implant on local expression of proteins that regulate 
glucose uptake. (A) Adiponectin, leptin, and insulin protein levels in epididymal fat 2 
weeks after implant measured by ELISA. Data normalized to naïve controls. n=5 mice 
per condition. (B) IGF-1 protein levels in epididymal fat measured by ELISA at various 
time points after scaffold implant. Data normalized to naïve controls. Statistics 
calculated using a two-way ANOVA with Tukey’s multiple comparisons test. * indicates 
p<0.05 versus sham at the corresponding time point, † indicates p<0.05 versus scaffold 
on Day 28. n=5 mice per condition. 
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Scaffold implant results in remodeling of the adipose tissue that decreases 
adipose tissue size. 
We next sought to understand why Glut1 is elevated in the adipose tissue 
following scaffold implant and began with a histological analysis of the implant site. 
Tissue sections from epididymal fat pads 10 days after scaffold implant revealed 
cellular infiltration and protein deposition not present in naïve fat pads (Fig. 2.6A 
versus 2.6B). The tissue remodeling did not spread throughout the entire fat pad 
but localized around irregular shape voids that are pieces of the scaffold dissolved 
during tissue processing (Fig. 2.6B). In fact, when inspecting adipose tissue distant 
from the implant site we could not detect differences in tissue structure between 
naïve adipose tissue and tissue that received scaffolds. That being said, we did 
note there was a small, but significant decrease in adipose tissue weight and 
adipocyte size in epididymal fat pads with scaffold implants compared to those 
from sham mice (Fig. 2.6F-G). Inspection of the implant site at high magnification 
revealed giant cells with acidophilic cytoplasm and multiple nuclei were in close 
association with pieces of the scaffold (Fig. 2.6C). Patches of fibrous tissue appear 
light pink and contain both mononuclear immune cells (circular nuclei) and 
fibroblasts (oval nuclei). Finally, vessels containing red blood cells are present 
throughout the implant site suggesting the implant environment is integrated with 
the host. Glut1 is ubiquitously expressed among cells in the body and is 
responsible for the basic supply of cells with glucose52. Glut1 exhibits highest 
expression levels in erythrocytes and endothelial cells, but is also found on 
macrophages, T cells, fibroblasts and adipocytes53–57. Thus, we conclude that 
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Figure 2.6. The effect of scaffold implant on epididymal fat. (A-E) Representative 
images of formalin fixed paraffin embedded tissue sections stained with hematoxylin 
and eosin. (A) Naïve epididymal fat and (B) epididymal fat 10 days after scaffold 
implant; scale bars are 500 µm. (C) Scaffold implant site at day 10; scale bar is 50 µm. 
(D-E) Representative images of adipocytes from mice receiving (D) sham surgery and 
(E) scaffolds 2 weeks after implant; scale bar is 50 µm. (F) Quantification of adipocyte 
area at 2 weeks. Data normalized to naïve; n=3 mice per condition. (G) Weight of 
epididymal fat at 2 weeks. Data normalized to naïve. n=5 mice per condition. Statistics 
calculated by an unpaired t-test; * indicates p<0.05 versus sham. (H) Cytokine protein 
levels in epididymal fat two weeks after scaffold implant measured by ELISA. Data 
normalized to naïve fat. n=4-6 mice per condition. 
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increased cellularity caused by scaffold implant is responsible for the three-fold 
increase in Glut1 (Fig. 2.4B) and the increased glucose uptake measured in 
epididymal fat implanted with scaffolds (Fig. 2.3A and 2.3B). Taken together, the 
data indicates that scaffold implant results in tissue remodeling that is localized to 
the implant site and characterized by the influx of many cells types that express 
Glut1. 
A logical concern with the level of immune infiltration seen after scaffold 
implant is there could be an increase in pro-inflammatory mediators that would 
lead to chronic low grade inflammation seen in mouse models and human patients 
with obesity58–60. We are not concerned by this because we found that scaffold 
implant appears to decrease TNF-a levels below those found in naïve fat and does 
not increase IL-6 at the 14-day time point (Fig. 2.6H). These findings are congruent 
with a recent publication demonstrating that PLG scaffold implant into the 
epididymal fat decreases IL-6 and TNF-a61. 
Enrichment of scaffold-recruited macrophages at the implant site correlates with 
increased IGF-1 expression. 
Our subsequent studies focused on understanding the source of elevated 
IGF-1 following scaffold implant (Fig. 2.5B). Recently, bone marrow derived 
macrophages were identified as a major source of IGF-1 in adipose tissue62. In our 
study, flow cytometry revealed that scaffold implant resulted in a threefold increase 
in macrophages as identified by expression of F4/80 and CD11b. In contrast, 
tissue from mice receiving sham surgery had similar macrophage content to naïve 
controls, which indicates the surgery alone does not recruit macrophages to the 
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Figure 2.7. The effect of resident tissue macrophage depletion on scaffold 
induced IGF-1 and Glut1 expression. (A) Number of F4/80 cells isolated from naïve 
epididymal fat and epididymal fat receiving sham surgery or scaffolds 14 days after 
implant. Data analyzed using a one-way ANOVA with Tukey’s multiple comparisons 
test. * indicates p<0.05 versus naïve, † indicates p<0.05 versus sham. n= 4-6 mice 
per condition. (B) Number of F4/80 cells isolated from naïve epididymal fat and 
epididymal fat 48 hours after intraperitoneal injection of clodronate liposomes. Data 
analyzed using an unpaired t-test; * indicates p<0.05 compared to naïve controls. n=5-
6 mice per condition. (C) Timeline of clodronate liposome injection and scaffold implant 
study. (D) Number of F4/80 cells isolated from the epididymal fat of mice receiving a 
clodronate liposome injection 48 hours prior to scaffold implant (Sc+CLD) and mice 
that received scaffolds but no clodronate liposome injection (Sc). (E) IGF-1 protein in 
epididymal fat of mice receiving a clodronate liposome injection 48 hours prior to 
scaffold implant and mice that only received scaffolds measured by ELISA. (F) 
Western blot for Glut1 in epididymal fat. (G) Quantification of band intensity. (D, E, G) 
Data analyzed using an unpaired t-test; * indicates p<0.05 compared to scaffold 
controls. n=3-5 mice per condition.  
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epididymal fat (Fig. 2.7A). To investigate if scaffold-recruited macrophages were 
the source of the elevated IGF-1, we utilized an intraperitoneal injection of 
clodronate liposomes to remove resident macrophages from the epididymal 
adipose tissue prior to scaffold implant. Flow cytometry confirmed that clodronate 
liposomes were effective in removing 70% of the resident macrophages 48 hours 
after a single intraperitoneal injection (Fig. 2.7B). Interestingly, 14 days after 
scaffold implant macrophage numbers in the epididymal fat were similar between 
the untreated and chlodronate-treated groups (Fig. 2.7D); however, there was a 
significant increase in IGF-1 in the epididymal fat of the chlodronate treated group 
(Fig. 2.7E). Since 70% of resident macrophages are removed with clodronate 
liposomes prior to scaffold implant (Fig. 2.7B), we conclude that 14 days after 
scaffold implant there is a higher number of scaffold-recruited macrophages in the 
epididymal fat of clodronate treated mice compared to controls. The data suggest 
that scaffold-recruited macrophages are responsible, at least in part, for the 
elevated IGF-1 detected 14 days after scaffold implant. We also investigated if 
clodronate liposome administration had an effect on Glut1 levels in the epididymal 
fat (Fig. 2.7F-G); however, Glut1 was unchanged. 
PLG scaffolds decrease adiposity and improve glucose tolerance of mice fed a 
high fat diet. 
In lean mice, scaffolds decreased epididymal fat pad weight (Fig. 2.6G) 
while increasing the tissue’s expression of Glut1 and IGF-1 (Fig. 2.4B and 2.4B). 
These effects correlated with decreased fasting blood glucose levels (Fig. 2.2.1A) 
and elevated basal glucose uptake at the implant site (Fig. 2.3B). These 
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Figure 2.8. Body composition and glucose tolerance of high fat diet fed mice 
two weeks after scaffold implant. (A) Timeline of the study. (B) Total body weight. 
(C) Total body fat. (D) Weight of epididymal (eWAT), inguinal (iWAT) and subscapular 
(sWAT) white adipose tissue. (E) Fasting blood glucose levels. (F) Intraperitoneal 
glucose tolerance test and (G) area under the curves. Statistics calculated by one-way 
ANOVA with a Tukey’s multiple comparisons test. * indicates p<0.05 compared to 
HFD, † indicates p<0.05 compared to HFD+Sh. n=8-13 mice per group. HFD = high 
fat diet, Sh = sham, Sc = scaffold, IPGTT = intraperitoneal glucose tolerance test, AUC 
= area under the curve. 
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findings led us to investigate if scaffolds could treat diet induced obesity and its 
associated prediabetic state. We utilized a common mouse model in which male 
C57BL/6 mice are fed a diet that is 60% fat. After one-week of the diet, total body 
fat doubled (Sup. Fig. 2.11A) and the mice exhibited glucose intolerance (a 
hallmark of prediabetes) characterized by elevated fasting blood glucose (Sup. Fig. 
2.11C) and increased area under the curve during an intraperitoneal glucose 
tolerance test (Sup. Fig. 2.11E). It was at this timepoint that we administered the 
scaffold-based intervention while keeping the mice on the high fat diet. One week 
following scaffold implant therapeutic effects seemed apparent but were not 
significant (Sup. Fig. 2.12). Two weeks after scaffold implant mice exhibited a trend 
of decreased total body fat (Fig. 2.8C). By weighing individual fat pads, we found 
that this trend was due in part to significant decreases in epididymal and inguinal 
fat pad weight (Fig. 2.8D). While there was a trend of decreased fasting blood 
glucose (Fig. 2.8E), glucose tolerance was significantly improved after two weeks 
of scaffold implant as indicated by an intraperitoneal glucose tolerance test (Fig. 
2.8F-G). We next measured IGF-1 and Glut1 in the epididymal fat of high fat diet 
 
Figure 2.9. IGF-1 and Glut1 in the epididymal fat of high fat diet fed mice two 
weeks after scaffold implant. (A) IGF-1 protein levels measured by ELISA. Data 
normalized to chow. (B) Western blot assessing Glut1 levels. (C) Quantification of band 
intensity. Data analyzed using a one-way ANOVA with a Tukey’s multiple comparisons 
test. * indicates p<0.05 versus HFD, † indicates p<0.05 versus HFD+Sh. n=3-5 mice 
per group. HFD = high fat diet, Sh = sham, Sc = scaffold. 
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fed mice two weeks after scaffold implant. We found that scaffold implant rescues 
a decrease in epididymal IGF-1 expression caused by the high fat diet (Fig. 2.8A) 
and increases Glut1 protein two-fold compared to mice on a high fat diet (Fig. 2.9B-
C). Taken together, these data demonstrate that PLG scaffold implant into the 
epididymal fat decreases fat pad size and improves glucose tolerance in mice 
challenged with a high fat diet and suggests that these effects are mediated by 
elevated IGF-1 and Glut1 at the implant site.  
2.4  Discussion. 
The overarching goal for this research is to develop tissue engineering 
platforms to correct adipose tissue dysfunction that underlies metabolic disease, 
such as impaired glucose uptake. In these studies, we discovered that porous PLG 
scaffolds decreased fasting blood glucose of healthy mice when implanted into the 
epididymal fat. Interestingly, the relative decrease in fasting blood glucose we 
attained is similar to that achieved after 3.5 weeks of treadmill training63. When 
assessing fasting glucose uptake through the injection of a fluorescent glucose 
tracer, we found the area in close proximity to the scaffold exhibited intense 
glucose uptake. This area localizes with cellular components of the host response 
observed in histological sections of the implant site. The localized increase in 
glucose uptake is striking and demonstrates that cells attracted by the scaffold 
have a substantial appetite for glucose, specifically when activated, such as during 
the tissue remolding that follows biomaterial implant53,64,65. Considering all the 
data, we propose that the mechanism of decreased blood glucose in response to 
PLG scaffolds is as follows. Scaffold implant into the fat results in a new 
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microenvironment that consists of blood vessels, extracellular matrix, fibroblasts, 
mononuclear immune cells, and multinucleated giant cells. Within this 
environment, cells degrade the scaffold into smaller pieces that are either removed 
from or integrated with the surrounding tissue. This environment requires high 
amounts of glucose relative to native fat and its glucose requirements can cause 
blood glucose levels to decrease in the fasted state. 
These findings raise an important question: Are the glucose lowering effects 
specific to PLG or can other materials cause this effect? As outlined above, we 
theorize the glucose lowering effect stems from the scaffold’s ability to induce and 
support cellular activity associated with the host response. Synthetic materials, 
such as PLG, support these cell-material interactions through protein 
adsorption66,67. One factor that greatly influences protein absorption is 
hydrophobicity68, thus we hypothesize that biomaterials with similar hydrophobic 
properties to PLG would result in similar amounts of protein absorption, leading to 
host responses that can lower blood glucose. In support of this hypothesis, 
scaffolds made of polycaprolactone, a polymer with comparable hydrophobicity to 
PLG, induce immune responses comparable to PLG scaffolds when implanted into 
the epididymal fat31,69–71; however, it is currently unknown if polycaprolactone 
scaffolds decrease blood glucose levels in mice. On the other hand, it is possible 
that the glucose lowering effect is specific to PLG because its degradation products 
are responsible. In support of this notion, lactate, which is released as PLG 
degrades, modulates cellular metabolism72,73. Especially relevant to the current 
work are reports that lactate increases expression of Glut1 in adipocytes74 and 
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inhibits macrophage inflammatory activity75. Thus, it is possible that the therapeutic 
effects of PLG scaffolds are linked to lactate release and tuning PLG properties to 
increase lactate release rate76 would enhance the scaffold’s ability to modulate 
blood glucose levels. 
Currently, it is unclear if the scaffold’s effect on blood glucose levels is 
permanent; however, we suspect that the effect is transient. We think that as the 
host response resolves and pieces of the scaffold are either removed or integrated 
with the surrounding tissue, cellular activity will diminish and so will the local 
glucose utilization at the scaffold implant site. Following this reasoning, there will 
be a point in time where glucose utilization gets low enough that blood glucose 
levels increase to normal, “naïve” levels. It is unclear when exactly blood glucose 
levels will return to normal, but the data in Figure 2.5B indicates that IGF-1 
expression at 4 weeks is significantly lower than IGF-1 expression at 1 and 2 
weeks. This suggests that the host response is resolving at 4 weeks and that blood 
glucose levels may return to normal around that time. We hypothesize that by 
engineering the scaffold to extend or augment cellular activities within the implant 
site (e.g. drug delivery, modulating the implant’s size, surface area, surface 
chemistry, degradation kinetics) the timeframe of lowered blood glucose could be 
extended. Indeed, augmenting the scaffold’s effect on glucose uptake is an active 
area of our research.  
When investigating protein expression in epididymal fat with scaffolds, we 
found substantial increases in Glut1 (three-fold) and IGF-1 (two-fold) compared to 
control tissue. While the exact cellular source of Glut1 is unclear (this glucose 
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transporter is ubiquitously expressed46), scaffold-recruited macrophages appear 
to be the cause of elevated IGF-1 levels. Our conclusion is supported by recent 
findings that macrophages produce high levels of IGF-1 and are a source of IGF-
1 in adipose tissue62,77. Increasing Glut1 and IGF-1 expression in the fat is exciting 
from the point of view of treating both prediabetes as well as diabetes. For 
example, Glut1 does not require insulin or any other hormone to participate in 
glucose uptake48,78. In contrast, Glut4, the principal glucose transporter in muscle 
and fat, requires insulin signaling for its translocation from intracellular stores to 
the cell surface before it is functional79. Thus, if the tissue is insulin resistant or if 
the patient is suffering from beta-cell failure associated with either type 1 or type 2 
of diabetes, elevating Glut4 expression is likely futile, but targeting Glut1 is a viable 
option. In support of this strategy, mice that overexpress Glut1 in their skeletal 
muscle exhibit a 30% decrease in fasting blood glucose levels and enhanced 
glucose uptake in their muscle that does not require insulin44. Regarding IGF-1, its 
receptor is homologous to the insulin receptor and shares many overlapping 
downstream signaling pathways. IGF-1 binding to its receptor (IGF-1R) results in 
Glut4 translocation and glucose uptake80,81; however, IGF-1 can also bind the 
insulin receptor, albeit with lower affinity than insulin, and promote glucose 
uptake82. Since the scaffold induces high levels of IGF-1 locally, this may cause 
glucose uptake in an insulin resistant tissue that requires high levels of receptor 
activation, or in a patient that is suffering from beta cell failure and no insulin is 
available. Taken together, PLG scaffolds deliver a “one-two punch” in treating 
glucose intolerance in tissues: (i) inducing expression of a glucose transporter that 
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does not require insulin and (ii) inducing high local levels of a molecule that acts 
like insulin. 
In terms of therapeutic applications, scaffolds implanted into the epididymal 
fat improved glucose tolerance in mice fed a high fat diet. In this model, glucose 
intolerance develops within 3 days83,84. The excessive intake of dietary fat causes 
rapid expansion of the epididymal adipose tissue, which becomes insulin resistant 
due to high levels of fatty acids in the tissue. The insulin resistance in the 
epididymal fat contributes to the glucose intolerant state83. The improvement in 
glucose tolerance in this study correlated with elevations in Glut1 and IGF-1 
suggesting that increased glucose uptake at the implant site played a role. High 
fat diet fed mice treated with scaffolds also had smaller epididymal fat pads, which 
agrees with our experiments in lean mice that showed scaffold implant decreased 
adipocyte cell size and epidydimal fat pad weight; the data indicate that the host 
response to the scaffold in the fat was responsible. We think that scaffolds 
decrease fat pad size because the cellular activity invoked to degrade and 
integrate it with fat pad utilizes not only glucose, but also fatty acids, which are 
provided by the surrounding adipocytes. As the tissue remodeling ensues, local fat 
stores are depleted, and the fat pad decreases in size. This explanation is 
supported by a large body of research indicating that cellular activity associated 
with wound healing is largely fueled by fatty acid metabolism85,86. Taken together, 
these findings demonstrate increased cellular activity in the adipose tissue caused 
by the scaffold is beneficial to mice fed the high fat diet because it mitigates the 
high levels of fatty acids and glucose that lead to the obese, prediabetic state. 
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This work indicates that the host response to PLG scaffolds protects mice 
from diet induced obesity and glucose intolerance. These results were unexpected, 
and somewhat ironic, since the biomaterials field has focused heavily on mitigating 
or preventing the host response to biomaterial implant because of its detrimental 
effects in some tissue engineering applications32,87. To our knowledge, we are the 
first to report a systemic metabolic effect (beneficial or otherwise) due to 
biomaterial implant. As is indicated by many extensive, highly cited, and even 
recent reviews66,67,88, the field has focused on the host response to biomaterials in 
the implanted tissue while the impact on distant tissues or systemic responses 
have been understudied or undetected. Our work raises the possibility that, in 
addition to PLG scaffolds, there are other tissue engineering constructs or 
implantable devices already in use that modulate physiology distant from the 
implant site. The organs of the body function in concert, and tissues commonly 
addressed by tissue engineers (e.g. bone and muscle) modulate each other’s 
physiology through endocrine signaling89. Thus, while it is paramount that novel 
and repurposed biomaterials for implantation do not negatively impact the local 
tissue, the field would be amiss if future studies did not address how tissue-
engineered environments can be leveraged to modulate physiology or pathology 
in distant organs. 
In conclusion, PLG scaffolds increase glucose uptake in the epididymal fat 
and decrease fasting blood glucose in healthy mice. Glut1 and IGF-1, which 
mediate glucose uptake, are elevated in the fat tissue after scaffold implant. 
Histological analysis of the implant site indicates increased cellularity in the 
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immediate vicinity of the scaffold and suggests several cell types involved in the 
host response are responsible for elevated Glut1 levels. Enrichment of scaffold-
recruited macrophages at the implant site correlated with increased IGF-1 levels, 
suggesting these macrophages are responsible for elevated IGF-1. The data 
indicate that the host response to a PLG scaffold imparts a metabolic load on the 
mouse that is sufficient to decrease systemic blood glucose levels, which is 
remarkable. Regarding therapeutic application, treatment with PLG scaffolds 
decreases adiposity and improves glucose tolerance in mice fed a high fat diet, 
indicating the increased cellular activity in the adipose tissue invoked by scaffold 
implant is protective against the overnutrition that makes the mouse obese and 
prediabetic. Thus, we conclude PLG scaffolds are a promising platform for treating 
metabolic disease since the polymer alone has beneficial effects and these 
devices are readily engineered for drug or cell delivery that may enhance their 
efficacy. More broadly, this work reaffirms that in addition to the local tissue 
responses induced by biomaterial implant, which are usually the focus of the field, 
there are systemic effects that may be leveraged for therapy. Finally, we 
hypothesize that further unraveling how the host response to PLG mitigates the 
metabolic complications of diet induced obesity will identify new drug targets and 
avenues for therapy. 
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2.5  Supplemental Results. 
 
Figure 2.10. Flow Cytometry Gating Strategy. Gating scheme and representative 
F4/80 versus CD11b plots used to identify macrophages in naïve adipose tissue, 
adipose tissue 48 hours after clodronate injections, and adipose tissue 14 days after 
implant of PLG scaffolds.  
Immune Cell Gating Scheme 




CLD 48 hours Scaff 14 days
 38 
 
Figure 2.11. Body composition and glucose tolerance in C57BL/6 mice one week 
after HFD feeding. (A) Fat mass and (B) lean mass from DEXA scans of mice kept on 
a chow diet and mice kept on a 60% high fat diet for one week. (C)  Fasting blood 
glucose. (D) Intraperitoneal glucose tolerance test conducted one week after starting 
mice on the HFD. (E) Area under the curve. Statistics calculated using an Unpaired T-





Figure 2.12. Effect of scaffolds on body composition and glucose tolerance of 
mice fed a high fat diet one week after scaffold implant. (A) Timeline of the study. 
(B) Body weight. (C) Total body fat measured by DEXA scans. (D) Fasting blood 
glucose measurements made 1 week after scaffold implant. (E) Intraperitoneal glucose 
tolerance test and (F) area under the curve completed 1 week after scaffold implant. 
Statistics calculated by one-way ANOVA with a Tukey’s multiple comparisons test. * 
represents p<0.05 compared to HFD control, † represents p<0.05 compared to 
HFD+Sh. For all conditions n=5 mice per condition. HFD = high fat diet, Sh = sham, 
and Sc = scaffold. 
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CHAPTER 3 
RESVERATROL DELIVERY FROM SCAFFOLDS TO THE 
EPIDIDYMAL ADIPOSE TISSUE DECREASES TOTAL BODY FAT 
AND IMPROVES GLUCOSE TOLERANCE IN MICE CHALLENGED 
WITH A HIGH FAT DIET 
 
3.1  Introduction. 
Obesity is a major burden on the United States healthcare system with over 
two thirds of the adult population classified as overweight and over one third as 
obese90. Adding to this burden is obesity’s association with type 2 diabetes, 
cardiovascular disease and certain types of cancer4. With respect to type 2 
diabetes, this link is undeniable; nearly 90% of those suffering from type 2 diabetes 
are overweight or obese10.  
There is no question that adipose tissue dysfunction constitutes a 
mechanistic link between the obese and diabetic disease states6. Healthy adipose 
tissue functions as an energy reservoir which stores lipids in times of caloric 
surplus and releases lipids in times of caloric deficit. However, the adipose tissue 
has a limited storage capacity, and excess lipid buildup that occurs during obesity 
leads to dysregulation of adipocytes, the most prevalent cells within the tissue12. 
Lipid accumulation is particularly troublesome in adipose tissue around internal 
organs (visceral fat)12. The excess lipid in visceral fat causes inflammation, which 
leads to the influx of inflammatory macrophages. Inflamed visceral fat then 
secretes large amounts of lipids into the bloodstream resulting in lipid build up in 
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peripheral tissues, such as the skeletal muscle and liver, causing insulin resistance 
in those tissues16. Eventually, insulin resistance throughout the body causes a 
state of glucose intolerance leading to hyperglycemia. Chronic hyperglycemia 
damages vital organs, including the pancreas, whose failure marks the onset of 
type 2 diabetes. 
The critical role of lipid accumulation in adipose tissue, in particular the 
visceral adipose tissue, in the development of glucose intolerance suggests 
treatment strategies focused on engineering visceral adipose tissue lipid utilization 
could represent a promising strategy for obese patients who are developing 
diabetes. Currently, the standard of care for obese diabetics, in combination with 
diet and exercise, is anti-diabetic medications that improve insulin sensitivity 
and/or promote insulin production. However, these medications fail to address the 
underlying adipose dysfunction and, in addition, have side effects that hinder their 
safety, patient compliance, and effectiveness20. 
Our lab is currently investigating the use of polymer scaffold implants to 
engineer the fat’s lipid metabolism in the visceral adipose tissue as a therapeutic 
strategy to treat obesity and its related disorders. In a previous study we 
discovered that the implant of scaffolds made of poly(lactide-co-glycolide) (PLG) 
containing no drug payload, decreased the epididymal adipose tissue (visceral 
adipose tissue of the mouse) weight in both healthy mice and mice challenged with 
a high fat diet, suggesting elevated metabolism of lipid stores91. These observed 
effects were attributed to the cellular remodeling in the adipose tissue caused by 
the host response to the polymer.  
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To further investigate the therapeutic effects of these scaffolds as well as 
investigate ways to augment this lipid burning effect, we encapsulated resveratrol 
(trans-3,5,4’-trihydroxystilbene), a naturally occurring polyphenol that has been 
shown to mimic the effects of caloric restriction92–94 within the matrix of our PLG 
scaffolds. Specifically, resveratrol has been shown to adipocyte lipid utilization by 
increasing expression of carnitine palmitoyltransferase 1 (CPT1)34, the rate limiting 
enzyme involved in fatty acid oxidation. This effect and others have been linked to 
decreased obesity and improved glucose tolerance in rodents and primates fed a 
high fat diet while treated with oral administration of resveratrol92,95. However, 
therapeutic efficacy requires high daily doses of resveratrol (30-400 mg/kg/day) in 
order to overcome resveratrol’s rapid first pass metabolism, which hinders its 
bioactivity35,96. However, delivery of resveratrol directly to the adipose tissue from 
polymer scaffolds could compensate for the molecule’s bioavailability issues and 
allow for extended therapeutic effects with minimal dosing.  
To test this hypothesis, we implanted resveratrol loaded PLG scaffolds into 
the epididymal adipose tissue and assessed the ability to reduce fat accumulation 
and improve glucose tolerance in a mouse model of diet induced obesity. In this 
mouse model, C57BL/6 mice are fed a diet containing high fat content and rapidly 
gain fat mass and become insulin resistant due to lipid accumulation in peripheral 
tissues after just one week83. Therefore, in order to test the ability of scaffolds to 
mitigate this lipid accumulation, we surgically implanted these scaffolds into the 
adipose tissue after one week of high fat diet feeding. Interestingly, resveratrol 
loaded scaffolds were able to reduce lipid accumulation and improve glucose 
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tolerance in high fat diet fed mice, however scaffolds containing no drug payload 
also had noticeable effects on these parameters.  
3.2    Methods. 
Particle Fabrication. 
Particles were produced by an oil-in-water emulsion-solvent evaporation 
technique. The oil phase consisted of a 3:1 mixture of dichloromethane (Sigma) 
and ethanol (Sigma) containing 6% w/v PLG (purchased from Evonik, 75:25 mol 
ratio lactide to glycolide, 0.76 dL/g) and 10mg/mL of trans-resveratrol (Sigma 
R5010). The aqueous phase consisted of 1% w/v poly(vinyl alcohol) (Sigma) 
dissolved in ultrapure water. The oil phase was homogenized with the aqueous 
phase using a 1:7 volume ratio with a benchtop homogenizer. The emulsion was 
then immediately added to ultrapure water and stirred for 5 hours to allow particles 
to harden and organic solvents to evaporate. Particles were collected via 
centrifugation, washed with ultrapure water, and lyophilized. 
Scaffold Fabrication. 
Scaffolds were fabricated by mixing PLG particles with 250-500 µm NaCl 
particles in a 1:30 ratio and the mixture was then pelleted in a die. Scaffolds were 
gas-foamed using 800 psi CO2 at room temperature in a pressure vessel. The salt 
porogen was removed by washing in ultrapure water. Complete salt removal was 
confirmed by scaffold weight and microscopy. Scaffolds that did not contain 
resveratrol were fabricated from particles produced using an oil phase that did not 
contain resveratrol or ethanol. From here on resveratrol loaded scaffolds are 
referred to as “resveratrol scaffolds” and scaffolds that do not contain resveratrol 
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are referred to as “blank scaffolds”. 
Quantification of Resveratrol within Scaffolds. 
Resveratrol scaffolds were dissolved in dimethyl sulfoxide (DMSO) and 
samples were loaded into a UV-Starâ 96 well plate (Greiner Bio-One) and 
scanned for absorption at 330 nm using a Biotek Synergy 2 plate reader. 
Resveratrol content was determined with an 8-point standard curve produced by 
making ½ dilutions of a 1 mg/mL resveratrol solution in DMSO. All resveratrol 
standards contained PLG at the same concentration as the scaffold samples.  
Animal Studies. 
Male C57BL/6J mice were purchased from Jackson Laboratory at 6 weeks 
of age. All animals were housed with ad libitum access to water and food in a 
temperature-controlled room with a 12:12 h light:dark cycle. All procedures were 
performed in accordance with NIH Guidelines for Care and Use of Animals and 
were approved by the Institutional Animal Care and Use Committee at the 
University of South Carolina. Mice were allowed to acclimate for two weeks prior 
to study.  
High Fat Diet Feeding. 
After two weeks of acclimation, mice were placed on a 60% high-fat diet 
(Research Diets D12492) while a control group was kept on a normal diet (Teklad 
8904). On a caloric basis, the high-fat diet consisted of 60% fat from lard, 20% 
carbohydrate, and 20% protein (total 5.24 kcal/g), whereas the normal diet 
contained 12% fat, 66%carbohydrate, and 22% protein (total 3.0 kcal/g). Mice were 
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kept on the high fat diet for one week prior to scaffold implantation and remained 
on the diet for the remainder of the experiment.  
Scaffold Implantation. 
Mice received scaffold implants into the epididymal fat as previously 
described31. Briefly, mice were anesthetized with a 2% mixture of isoflurane and 
oxygen (2 L/min), and the abdominal midline was shaved and prepped in a sterile 
fashion. Following a lower abdominal midline incision, each epididymal fat 
pad and wrapped around the scaffolds so that the scaffolds were in the center of 
the tissue. The abdominal wall was then closed with a running stitch, and the skin 
was closed with wound clips. All mice received two scaffolds per fat pad (i.e. each 
mouse received 4 scaffolds).  
Duel Energy X-Ray Absorptiometry (DEXA).  
Body composition was assessed using DEXA scans (Lunar PIXImus). Each 
mouse was anesthetized for the duration of the procedure (5 min) by exposure to 
2% isoflurane-oxygen gas via a nose cone. Each mouse was placed on the 
scanner bed in the prone position, with the limbs and tail stretched away from the 
body. One scan per mouse was performed and analyzed with PIXImus software 
(Lunar). The head was excluded from calculation using a manual ROI. The 
PIXImus was calibrated with an aluminum/Lucite phantom (corresponding to bone 
mineral density = 0.0592 g/cm2 and 12.5% fat) on each day of testing according 




Intraperitoneal Glucose Tolerance Test. 
Mice were fasted for 6-hours before receiving injections of D-glucose into 
the intraperitoneal cavity. Glucose administered was normalized to the lean mass 
calculated via a DEXA scan that was conducted one-day prior (2g glucose per kg 
lean mass). Blood samples were collected via a tail vein prick at 0, 15, 30, 60, 90, 
and 120 minutes after glucose administration. Glucose measurements were 
obtained using a handheld glucose meter (Accu-Chek Nano, SmartView).  
Food Intake Measurements. 
Food was weighed at the beginning and end of each week and the total 
grams of food consumed was calculated. To obtain kcal per mouse, weight of food 
consumed was normalized by the number of mice in the cage and multiplied by 
the calorie density in the food (5.24 kcal/gram). 
Enzyme Linked Immunosorbent Assay. 
Blood was collected from mice fasted for 6 hours retro-orbitally into EDTA 
coated tubes, spun down at 10,000 g, and plasma was isolated. Insulin ELISA kit 
was purchased from ALPCO. The assay was performed according to the 
manufacturer’s instructions.  
Western Blotting. 
Tissue samples were homogenized in RIPA buffer (Thermo Scientific) 
supplemented with protease inhibitor cocktail (Thermo Scientific), phospho-stop 
(Roche), and phenylmethane sulfonyl fluoride (Sigma). Following homogenization, 
protein was isolated via centrifugation at 18,000 g for 45 minutes. Protein 
concentrations were determined using a BCA assay (Thermo Scientific). Lysates 
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(30 ug adipose tissue, 100 ug gastrocnemius and liver) were separated by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were then transferred 
to a nitrocellulose membrane (GE Healthcare Life Sciences) and incubated with 
appropriate antibodies. Secondary antibody was a horseradish peroxidase (HRP)-
conjugated antirabbit immunoglobulin G (IgG) grown in goat (Abcam). Proteins 
were visualized using SuperSignal West Pico substrate (Thermo Scientific). 
Antibodies to total Akt, phospho-Akt ser 473, and GAPDH were purchased from 
Cell Signaling Technology (1:1000 dilution). The antibody for Glut4 was purchased 
from Sigma Aldrich (1:1000 dilution). The antibody for CPT1A was purchased from 
Abcam (1:1000 dilution). 
Resveratrol Extraction from Epididymal Fat Pads. 
 Resveratrol was extracted from epididymal fat pads using a technique 
derived from the work of Juan et al. Each fat pad was added to 2 mL of an acidified 
methanol solution consisting of 80% methanol (v/v), 17.5% ultrapure water, 2.5% 
acetic acid and 10µL of 15% (v/v) ascorbic acid. Fad pads were minced finely with 
scissors and homogenized using a Polytron tissue homogenizer (Kinematica). The 
homogenizer was cleaned twice with 1mL of the acidified methanol solution 
resulting in a final volume of 4mL per tissue. Following homogenization, samples 
were vortexed for 5 minutes and centrifuged at 3,000 g for 30 minutes at 4°C.  The 
supernatant was transferred to a clean tube and the solid residue was treated 2 
more times with the procedure outlined above. The supernatant was then reduced 
to a final volume of ~1mL with a rotary evaporator, passed through a 3 kDa 
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molecular weight cutoff filter, and stored in an amber vial at -20 oC prior to HPLC 
analysis.  
A Thermo Ultimate 3000 binary gradient system was used for HPLC 
analysis. The column used was a Chromegabond WR C18 and the flow rate was 
kept at 0.2 mL/min. The UV detector was Agilent G1315B Diode Array Detector 
set for 306nm. Solvent A was water and Solvent B was Acetonitrile. From 0-30min 
solvent was 90% A and 10% B. From 30min to 31 min solvent was 5% A and 95% 
B. From 31min on solvent was 90% A and 10% B. A fresh stock of trans-resveratrol 
was used to determine the correct elution time. HPLC/UV-Vis was used to detect 
resveratrol in the stock solution and the samples extracted from epididymal fat. 
Statistical Analysis. 
Data is presented as mean ± standard error of the mean. All statistical 
analyses were conducted using Prism software version 8 (GraphPad). Data sets 
comparing three or more groups were analyzed using a one-way ANOVA with 
Tukey’s multiple comparisons test. Data sets comparing two or more groups over 
time were analyzed using a two-way ANOVA with Tukey’s multiple comparisons 
test. P values less than 0.05 were considered significant.  
3.3   Results. 
Characterization of scaffolds.  
Representative SEM images of a scaffold are presented in Figure 3.1. 
Scaffold size and structure was unaffected by encapsulating resveratrol into the 
polymer matrix. Scaffolds were 5 mm in diameter and 2 mm in height with an 
average pore size of 370 ± 58 µm. Drug loading was 44.7 ± 3.2 µg of resveratrol 
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per mg of polymer. Blank and resveratrol scaffolds had similar weights (Table 3.1); 
thus, the only difference between the two types of scaffolds was resveratrol 
content. 
Table 3.1. Resveratrol loading and scaffold weights.  
 
Impact of scaffolds on mice challenged with a high fat diet.  
Daily oral delivery of resveratrol protects mice from high fat diet induced 
obesity and glucose intolerance. We hypothesized we could protect mice from a 
high fat diet with a single administration of resveratrol delivered over time through 
a scaffold implanted into the epididymal fat. The experimental timeline is depicted 
in Figure 3.2A. After one week of high fat diet, we implanted the scaffolds and then 
continued the mice on the diet for an additional five weeks. Each mouse received 
two scaffolds per fat pad. The resveratrol dose was calculated to be 272 
 
Figure 3.1. Images of a typical scaffold. Scanning electron microscope images of a 
scaffold. (A) Top profile. (B) Cross sectional profile. Scale bar is 1mm.  
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± 21 µg or ~14 mg/kg. Five weeks after scaffold implant, mice with scaffolds, 
regardless of resveratrol content, gained significantly less weight than the control 
mice that received the scaffold implant procedure, but no scaffold, which are 
referred to as “sham” from this point on (Figure 3.2B). Body composition analysis 
using DEXA indicated that mice with resveratrol scaffolds gained significantly less 
body fat compared to sham mice. The mice with blank scaffolds showed trends of 
lower body fat, but statistical significance (p<0.05) was not achieved (Figure 3.2C). 
These effects occurred without significant changes in food consumption between 
 
Figure 3.2. Effect of scaffolds on body composition in high fat diet fed mice. (A) 
Timeline of the study. (B) Percent change in body weight relative to the day of scaffold 
implant. (C) Percent change in fat mass relative to the day of scaffold implant. (D) 
Weekly kcal intake per mouse over the 5-week experiment. For body weight and 
composition, statistics were calculated by two-way ANOVA with a Tukey’s multiple 
comparisons test. For food consumption, statistics were calculated by one-way ANOVA 
with a Tukey’s multiple comparisons test. * p<0.05 versus HFD+Sh. For all conditions 
and timepoints n=4-5 mice. ND = normal diet; HFD = high fat diet; Sh = sham surgery; 
Sc = blank scaffold; Rsv = resveratrol scaffold. 
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the high fat diet fed groups (Figure 3.2D). Taken together, the data indicate that 
resveratrol scaffolds decrease fat mass accumulation caused by the high fat diet 
and achieves this effect through means other than decreasing food intake.  
In this mouse model of diet induced obesity, reductions in weight gain, 
specifically fat mass, often correlate with improved insulin sensitivity and glucose 
tolerance. Mice that received scaffolds, regardless of resveratrol content, had 
lower fasting insulin levels, but identical fasting glucose levels compared to the 
sham mice, indicating whole-body insulin sensitivity was improved in mice with 
scaffolds (Figure 3.3A-B). However, an intraperitoneal glucose tolerance test 
revealed that only the resveratrol group had a greater ability to clear a load of 
glucose from the bloodstream compared to the sham group (Figure 3.3C-D). 
 
Figure 3.3. Fasting insulin and glucose levels and glucose tolerance 5 weeks 
after scaffold delivery in high fat diet fed mice. (A) Fasting insulin measured in 
plasma by ELISA. (B) Fasting glucose measured in whole blood by glucometer. (C) 
Absolute blood glucose versus time during an intraperitoneal glucose tolerance test 
and (D) area under the curve. Statistics were calculated by one-way ANOVA with a 
Tukey’s multiple comparisons test. *p<0.05 versus HFD+Sh. n=4-5 mice per group.  
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Taken together, the data indicate that under fasting conditions, scaffolds are 
sufficient to improve insulin’s control of blood glucose levels; in contrast, when 
challenged with a bolus of glucose, resveratrol scaffolds are required to improve 
glucose clearance from the bloodstream. 
The effect of scaffolds on CPT1 expression in the epididymal fat.  
 The observed reduction in total body fat paired with no changes in caloric 
intake led us to investigate the effect of scaffolds on epididymal fat pad size and 
protein levels of carnitine palmitoyltransferase 1 (CPT1), the rate limiting enzyme 
in fatty acid oxidation. The hypothesis being that decreases in epididymal fat 
 
Figure 3.4. Effect of scaffolds on CPT1 in the epididymal fat. Epididymal fat pad 
weights, representative western blots, and band quantification for carnitine 
palmitoyltransferase 1 (CPT1) in the epididymal fat (A-C) five weeks and (D-F) two 
weeks after implant. Statistics were calculated by one-way ANOVA with a Tukey’s 
multiple comparisons test. * represents p<0.05 compared to HFD+Sh, † represents 
p<0.05 compared to HFD+Sc. n=4-5 mice per group. 
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contributed to overall decreases in total body fat and that decreases in epididymal 
fat were due to elevated levels of fatty acid utilization, for which CPT1 is an 
accepted marker. Five weeks after scaffold implant, we did not detect any 
differences between epididymal fat pad size or levels of CPT1 among the high fat 
diet fed groups (Figure 3.4A-C); therefore, in a separate cohort of animals, 
following the exact experimental design depicted in Figure 2a, we conducted these 
measurements two weeks after scaffold delivery. At this time point, we did not 
detect significant differences between epididymal fat pad weight between the high 
fat diet fed groups, although the resveratrol group exhibited a trend of decrease 
(Figure 3.4D); however, CPT1 protein was significantly higher in the epididymal fat 
of the resveratrol scaffold group compared to the blank scaffold group and the 
sham control (Figure 3.4E-F). Additionally, mice receiving blank scaffolds showed 
significant elevations in CPT1 in the epididymal fat compared to sham controls, 
suggesting scaffolds alone also elevate fatty acid oxidation. Taken together, the 
data indicate that blank scaffolds increase levels of CPT1 in the epididymal fat 2 
weeks after implant and this effect is augmented by resveratrol delivery. 
Furthermore, the data suggest that increases in fatty acid oxidation in the 
epididymal fat contributes to the decreased levels of total body fat we measured 




Figure 3.5. Assessment of cellular infiltration and CPT1 expression within 
scaffold implants. Representative images of epididymal adipose tissue sections from 
high fat diet fed mice receiving a sham surgery, blank scaffold implant, or resveratrol 
scaffold implant. Sections are from two weeks after surgery/implant. (A-F) Hematoxylin 
and eosin staining. (G-L) Immunohistochemistry staining for CPT1. Scale bars 
represent 500µm for 4x images and 50µm for 40x images. 
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Distribution of CPT1 expression within the epididymal fat.  
 In order to better understand the cellular changes occurring within the 
epididymal fat that lead to elevated CPT1 expression at the two-week time point, 
tissue sections from mice on the two-week high fat diet study were evaluated using 
hematoxylin and eosin staining. Large amounts of cellular infiltration were 
observed in mice receiving blank and resveratrol scaffolds relative to mice 
receiving the sham surgery (Figure 3.5A-C). Inspection at higher magnification 
showed an overall similar response to both scaffold types, however the epididymal 
adipose tissue from receiving resveratrol scaffolds showed trends of higher eosin 
staining, suggesting the possibility of greater extracellular matrix deposition 
(Figure 3.5D-F). Immunohistochemistry staining was then used to better visualize 
cells highly expressing CPT1. Interestingly, CPT1 was seen expressed highest in 
cells recruited to the epididymal adipose tissue by both scaffold types (Figure 
3.5G-I). Further inspection of the implant site did not reveal any obvious 
differences between cells expressing CPT1 in blank vs resveratrol scaffolds 
(Figure 3.5J-L). However, it was noticed that the multinucleated giant cells which 
could be found in adipose tissue from both scaffold types, expressed high levels 
of CPT1. 
Resveratrol content in epididymal fat two and five weeks after scaffold implant.  
 While the therapeutic effects of resveratrol delivery were apparent five 
weeks after scaffold implant, it was unclear if resveratrol was still present in the 
epididymal fat at that time point. To address this question, we measured 
resveratrol in epididymal fat pads two and five weeks after scaffold implant using 
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HPLC (Week 2 and Week 5, respectively, Figure 3.6). For comparison, we also 
analyzed epididymal fat pads that did not receive scaffolds in vivo but were 
processed with either two fresh resveratrol scaffolds (Sc+Rsv, Figure 3.6) or two 
fresh blank scaffolds (Sc, Figure 3.6). Two scaffolds were used because in the in 
vivo study mice received two scaffolds per fat pad. HPLC indicated that resveratrol 
was present within the epididymal fat at both two and five weeks after scaffold 
implant, with approximately 2% of the initial resveratrol dose remaining at two 
weeks and approximately 1% remaining at five weeks (Figure 3.6).  
3.4  Discussion. 
 The overarching goal for the research is to develop bioengineering 
strategies to treat metabolic disorders such as obesity and its associated insulin 
resistant state. In this work, we engineered polymer scaffolds to release resveratrol 
 
Figure 3.6. Resveratrol content in epididymal fat two and five weeks after 
scaffold implant. (A) HPLC chromatograms depicting resveratrol content in 
epididymal fat two and five weeks after implanting resveratrol scaffolds. For 
comparison, epididymal fat pads that did not receive scaffolds but were homogenized 
with either fresh resveratrol scaffolds (Sc+Rsv) or blank scaffolds (Sc) were included 
for comparison. (B) Resveratrol content in the epididymal fat depicted as peak area 
calculated from HPLC chromatograms. n = 3 mice per group. 
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following their implant into epididymal fat pads. Resveratrol delivery from the 
scaffolds decreased total body fat and improved glucose tolerance fed a high fat 
diet designed to induce fat gain and insulin resistance, which are two key goals for 
treating obese diabetics, a patient population that is difficult to treat. Resveratrol is 
a small molecule with anti-obesity and anti-diabetic properties notorious for its poor 
bioavailability that requires large oral doses administered daily in order to realize 
its therapeutic effects. For example, mice94,95,97,98, rats99–101, rhesus monkeys92 
and humans93,102,103 require doses that range from 20-400 mg/kg/day to induce 
weight loss, improve glucose tolerance, and/or decrease insulin resistance. In 
stark contrast to these large and frequent doses, scaffolds achieved therapeutic 
effects with a single administration and a resveratrol dose equivalent to 14 mg/kg. 
Our results demonstrate the potential of biomaterial implants to address 
bioavailability issues that hinder the therapeutic potential or translation of small 
molecule drugs. Furthermore, while the beneficial effects of oral resveratrol 
delivery on obesity and insulin resistance are established, ours is the first study 
demonstrating that resveratrol delivery directly to the visceral adipose tissue can 
induce similar effects with a substantially lower, single dose. 
We found that blank scaffolds decreased total body weight, which was likely 
due to decreased total body fat, although we did not have sufficient power to detect 
significance. Interestingly, there was no change in epididymal fat pad weight 
suggesting that fat accumulation was decreased elsewhere. Blank scaffolds also 
decreased plasma insulin levels indicating that the mice were more insulin 
sensitive compared to the sham control group. Taken together, these findings 
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suggest that lipid accumulation in the lean tissue was decreased by blank scaffolds 
because lipid accumulation in the skeletal muscle and liver are major drivers of 
insulin resistance in high fat diet fed mice83. 
If lipid accumulation was decreased in the lean tissue, what was the fate of 
this lipid? We found that blank scaffolds increased CPT1 in the epididymal fat, 
which is the rate limiting enzyme in fatty acid oxidation 104 and an accepted marker 
for increased fatty acid utilization 105. Thus, we propose that scaffolds increased 
lipid utilization in the epididymal fat, which led to decreased lipid accumulation in 
lean tissues, lower body fat, and improved insulin sensitivity (as measured by 
plasma insulin levels). 
An important question is, why do scaffolds increase CPT1 expression in the 
epididymal fat? Implanting scaffolds into the epididymal fat results in cellular 
infiltration in the immediate vicinity of the scaffold (Figure 3.5). Many of these cells 
are macrophages31,61 that express the anti-inflammatory markers CD206 and 
Arginase 161. The CPT1 isoform we measured (CPT1A), is the isoform expressed 
by macrophages64. Furthermore, when a biomaterial is too large to allow for 
macrophage phagocytosis, multinucleated giant cells are formed via macrophage 
fusion 106. Immunohistochemistry staining revealed the multinucleated cells that 
from in the adipose tissue as a response to our biomaterial implants highly express 
CPT1 (Figure 3.5). In addition, CD206 and arginase levels correlate with CPT1 
levels in macrophages because they are all upregulated during alternative 
activation107, which we have demonstrated occurs when these scaffolds are 
implanted into epididymal fat61. Taken together, we hypothesize that the 
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macrophages and multinucleated giant cells that accumulate in the adipose tissue 
following scaffold implant are responsible for the elevated CPT1 levels and that 
their activity within the implant site leads to decreased total body fat by elevating 
the net utilization of fatty acids within the epididymal adipose tissue. 
We also found that resveratrol scaffolds increased CPT1 to a greater 
degree than blank scaffolds. While immunohistochemistry did not reveal any 
obvious differences in CPT1 expression within the cellular infiltration seen in blank 
and resveratrol scaffolds, resveratrol has been demonstrated to elevate CPT1 
expression in adipocytes. In adipocytes, CPT1 expression is controlled through the 
activation of PPARg, which resveratrol and its metabolites can bind and activate108. 
Furthermore, resveratrol treatment increases CPT1 expression in cultured 
adipocytes34,109. Based on these published studies, we propose that resveratrol 
scaffolds may increase CPT1 levels in the adipocytes in the epididymal fat; 
however, it is possible that resveratrol increases CPT1 levels in macrophages or 
other stromal vascular cells that reside within the scaffold implant site as well and 
these effects were unable to be seen using immunohistochemistry. To our 
knowledge, the impact of resveratrol on CPT1 expression in non-adipocytes has 
not been reported. 
Considering all the data, we propose the following mechanism for the 
scaffold’s therapeutic effects on mice fed a high fat diet. Scaffolds elevate CPT1 
expression in the epididymal fat, which is further augmented by resveratrol. We 
hypothesize that this increases fatty acid utilization locally and decreases fatty acid 
accumulation throughout the mouse and, therefore, total body fat. Increased fatty 
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acid utilization at the scaffold implant site and decreased fatty acid accumulation 
in other tissues improves whole body insulin resistance reflected in the decreased 
plasma insulin levels. Overall, scaffold implant into the epididymal fat and 
resveratrol delivery exert exciting therapeutic effects on body composition, insulin 
resistance, and glucose tolerance in mice fed a high fat diet. 
HPLC indicated that resveratrol was still present in the epididymal fat at 
both two and five weeks after scaffold implant, with approximately 2% of the initial 
dose remaining at two weeks and approximately 1% remaining at five weeks. 
These are not trivial amounts of drug. We delivered ~136 µg of resveratrol to a fat 
pad. At 2 weeks the fat pads weighed 350 mg and at 5 weeks they weighed 1000 
mg (Figure 3.4). Taking the density of fat to be 0.9 mg/mL 110, the concentration in 
the tissue might have been 35 µM at 2 weeks and 5 µM at 5 weeks if the drug was 
evenly distributed throughout the tissue. For comparison, resveratrol at 25 µM is 
sufficient to induce CPT1 expression in cultured adipocytes 34. Moving forward with 
our approach, an obvious improvement would be to decrease the rate of drug 
release, which we hypothesize would increase the overall efficacy and the 
therapeutic window of the resveratrol scaffold. We believe this could be 
accomplished through decreasing the specific surface area of the scaffold for drug 
delivery and work is currently underway developing the next generation of 
scaffolds to control lipid utilization and storage in adipose tissue for the treatment 
of obesity and other metabolic syndromes. 
One drawback to this therapeutic approach is the invasiveness of the 
implant procedure. The visceral adipose tissue is located within the abdominal 
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cavity therefore a surgical procedure is required to place the scaffold in the tissue 
of interest. However, visceral adipose tissue has been shown to have lower lipid 
storage capacity than subcutaneous counterparts12 and thus require less lipid 
accumulation to become dysregulated. Additionally, the secretion of inflammatory 
cytokines from visceral adipose tissue has been linked to systemic inflammation in 
obese humans111. While we believe that these reasons support the choice of the 
visceral adipose tissue for these studies, future studies will be aimed at 
investigating if these effects can be repeated in other fat pads in the body, 
specifically subcutaneous fat pads such as the inguinal fat.  
 In conclusion, implanting poly(lactide-co-glycolide) scaffolds into the 
epididymal fat decreases body weight in mice fed a high fat diet and body 
composition analysis via DEXA suggests this effect is due to decreased total body 
fat. Mice with scaffolds also had plasma insulin and blood glucose levels on par 
with mice fed a chow diet indicating an improvement in whole body insulin 
sensitivity. Engineering the scaffolds to release resveratrol led to a significant 
reduction in total body fat and an enhanced ability to clear a bolus of glucose from 
the blood stream during an intraperitoneal glucose tolerance test. While epididymal 
fat pad weights were unchanged for either scaffold group, carnitine 
palmitoyltransferase 1 (CPT1), the rate limiting enzyme in fatty acid oxidation, was 
increased in the scaffold group and this expression was further enhanced by 
resveratrol. Mechanistically, we propose that scaffolds increase fatty acid oxidation 
in the epididymal fat, an effect that is enhanced by resveratrol, and this leads to 
decreased lipid deposition in lean tissue throughout the mouse, decreasing total 
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body fat and whole-body insulin resistance. Regarding the enhanced performance 
of the resveratrol group during the glucose tolerance test, we propose that 
resveratrol delivery to the epididymal fat enhanced its ability for glucose uptake 
compared with fat that received blank scaffolds. Remarkably, the enhancements 
in therapy with resveratrol are achieved with a single dose of 14 mg/kg, which is a 
substantial improvement over daily oral doses in the range of 20-400 mg/kg 
reported in the literature. Thus, we conclude that delivering resveratrol directly to 
the adipose tissue is a superior approach compared to the oral route. Finally, 
HPLC of epididymal fat extracts indicated that 98% of the resveratrol was released 
after two weeks with 99% released after 5 weeks. The similarities in performance 
between the blank scaffolds and those engineered for resveratrol delivery, coupled 
with the finding that only 2% of the drug remains after two weeks, suggest that 
modifying the scaffold to slow resveratrol delivery and extend its residence in the 
tissue may improve overall efficacy and extend the therapeutic window. In addition, 
further unraveling the cellular and molecular players that underly how scaffolds 
that are not modified with resveratrol improve metabolic health in diet induced 
obese mice is expected to inform the design of the next generation of 






IMPLANT OF RESVERATROL SCAFFOLDS INTO THE 
EPIDIDYMAL ADIPOSE TISSUE ACCELERATES THE RECOVERY 
FROM DIET INDUCED OBESITY WHEN COMBINED WITH A 
SWITCH TO A NORMAL DIET. 
4.1. Introduction. 
 Rates of obesity have steadily increased over the past decade with nearly 
half of adults projected to be classified as obese by 20303. During obesity, excess 
caloric intake results in the rapid expansion of the adipose tissue, however this 
expansion proves to be detrimental to the proper functioning of the tissue. The 
adipose tissue in obese individuals becomes dysregulated, resulting in secretion 
of fatty acids and inflammatory cytokines into the bloodstream where they 
accumulate in undesired tissues such as the skeletal muscle and liver83. The 
dysregulation of the adipose tissue represents a mechanistic link between obesity 
and its associated comorbidities and comortalities. Of all the associated disease 
states associated with obesity, none is as tightly linked as type 2 diabetes. Over 
90% of type 2 diabetes are also obese highlighting the connection between the 
two conditions10.  
 Current treatments for obesity revolve around lifestyle changes such as diet 
and exercise. However, many patients fail to strictly adhere to these lifestyle 
changes. Reasons for non-compliance are multifactorial, some of the more 
commonly cited complaints from patients include a lack of motivation, failure to see 
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noticeable progress, and the inability to adhere to therapies due to a physical 
injury19,20. Due to these reasons and more, the success of lifestyle changes in 
treating obesity associated type 2 diabetes has been estimated to be as low as 
10%20. This highlights a need for the develop treatment platforms that help 
promote the shift from an obese to lean state.  
 Our lab is currently investigating the use of drug delivery from polymer 
scaffolds implanted into the adipose tissue as a method to correct the dysfunction 
in the adipose tissue brought on by obesity. These scaffolds are made out of 
poly(lactide-co-glycolide) an FDA approved biomaterial and the scaffolds alone 
have been shown to protect mice from obesity and glucose intolerance91. To 
improve upon these effects, resveratrol, a natural polyphenol shown to have lipid 
reducing effects was encapsulated within the polymer matrix of our scaffolds. 
Previous studies have demonstrated that incorporation of resveratrol extends the 
protective effects of the scaffold implant, however little is known about how well 
they combine with healthy dietary changes. This is important for two reasons: (1) 
in the clinical setting pharmacological treatments are prescribed alongside lifestyle 
changes such as diet and exercise and (2) previous studies have shown 
dysregulation of the adipose tissue persists even after healthy lifestyle changes 
occur112. Therefore, the current study will investigate the ability of resveratrol 
scaffolds to restore the adipose tissue to a healthy state when combined with a 
switch from a high fat diet, which induces obesity and glucose intolerance, to a 





Particles were produced by an oil-in-water emulsion-solvent evaporation 
technique. The oil phase consisted of a 3:1 mixture of dichloromethane (Sigma) 
and ethanol (Sigma) containing 6% w/v PLG (purchased from Evonik, 75:25 mol 
ratio lactide to glycolide, 0.76 dL/g) and 10mg/mL of resveratrol (Sigma). The 
aqueous phase consisted of 1% w/v poly(vinyl alcohol) (Sigma) dissolved in 
ultrapure water. The oil phase was homogenized with the aqueous phase using a 
1:7 volume ratio with a benchtop homogenizer. The emulsion was then 
immediately added to ultrapure water and stirred for 5 hours to allow particles to 
harden and organic solvents to evaporate. Particles were collected via 
centrifugation, washed with ultrapure water, and lyophilized. 
Scaffold Fabrication. 
Scaffolds were fabricated by mixing PLG particles with 250-500 µm NaCl 
particles in a 1:30 ratio and the mixture was then pelleted in a die. Scaffolds were 
gas-foamed using 800 psi CO2 at room temperature in a pressure vessel. The salt 
porogen was removed by washing in ultrapure water. Complete salt removal was 
confirmed by scaffold weight and microscopy. Scaffolds that did not contain 
resveratrol were fabricated from particles produced using an oil phase that did not 
contain resveratrol or ethanol. From here on resveratrol loaded scaffolds are 
referred to as “resveratrol scaffolds” and scaffolds that do not contain resveratrol 
are referred to as “blank scaffolds”. 
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Quantification of Resveratrol within Scaffolds. 
Resveratrol scaffolds were dissolved in dimethyl sulfoxide (DMSO) and 
samples were loaded into a UV-StarÒ 96 well plate (Greiner Bio-One) and 
scanned for absorption at 330 nm using a Biotek Synergy 2 plate reader. 
Resveratrol content was determined with an 8-point standard curve produced by 
making ½ dilutions of a 1 mg/mL resveratrol solution in DMSO. All resveratrol 
standards contained PLG at the same concentration as the scaffold samples.  
Animal Studies. 
Male C57BL/6J mice were purchased from Jackson Laboratory at 6 weeks 
of age. All animals were housed with ad libitum access to water and food in a 
temperature-controlled room with a 12:12 h light:dark cycle. All procedures were 
performed in accordance with NIH Guidelines for Care and Use of Animals and 
were approved by the Institutional Animal Care and Use Committee at the 
University of South Carolina. Mice were allowed to acclimate for two weeks prior 
to study.  
High Fat Diet Feeding. 
After two weeks of acclimation, mice were placed on a 60% high-fat diet 
(Research Diets D12492) while a control group was kept on a normal diet (Teklad 
8904). On a caloric basis, the high-fat diet consisted of 60% fat from lard, 20% 
carbohydrate, and 20% protein (total 5.24 kcal/g), whereas the normal diet 
contained 12% fat, 66% carbohydrate, and 22% protein (total 3.0 kcal/g). Mice 
were switched to the normal diet at the time of scaffold implantation and remained 
on the diet for the remainder of the experiment.  
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Scaffold Implantation. 
Mice received scaffold implants into the epididymal fat as previously 
described31. Briefly, mice were anesthetized with a 2% mixture of isoflurane and 
oxygen (2 L/min), and the abdominal midline was shaved and prepped in a sterile 
fashion. Following a lower abdominal midline incision, scaffolds were wrapped in 
each epididymal fat pad. The abdominal wall was then closed with a running stitch, 
and the skin was closed with wound clips. All mice received two scaffolds per fat 
pad (4 scaffolds per mouse). 
Intraperitoneal Glucose Tolerance Test. 
Mice were fasted for 6-hours before receiving injections of D-glucose into 
the peritoneal cavity. Glucose administered was normalized to the body weight (2g 
glucose per kg body weight). Blood samples were collected via a tail vein prick at 
0, 15, 30, 60, 90, and 120 minutes after glucose administration. Glucose 
measurements were obtained using a handheld glucose meter (Accu-Chek Nano, 
SmartView).  
Food Intake Measurements. 
Food was weighed at the beginning and end of each week and the total 
grams of food consumed was calculated. To obtain kcal per mouse, weight of food 
consumed was normalized by the number of mice in the cage and multiplied by 
the calorie density in the food (5.24 kcal/gram). 
Western Blotting. 
Tissue samples were homogenized in RIPA buffer (Thermo Scientific) 
supplemented with protease inhibitor cocktail (Thermo Scientific), phospho-stop 
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(Roche), and phenylmethane sulfonyl fluoride (Sigma). Following homogenization, 
protein was isolated via centrifugation at 18,000 g for 45 minutes. Protein 
concentrations were determined using a BCA assay (Thermo Scientific). Lysates 
(30 ug adipose tissue, 100 ug gastrocnemius, and 25 ug liver) were separated by 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were then 
transferred to a nitrocellulose membrane (GE Healthcare Life Sciences) and 
incubated with appropriate antibodies. Secondary antibody was a horseradish 
peroxidase (HRP)-conjugated antirabbit immunoglobulin G (IgG) grown in goat 
(Abcam). Proteins were then visualized using SuperSignal West Pico substrate 
(Thermo Scientific). Antibodies to total Akt, phospho-Akt ser 473, ATGL, and 
GAPDH were purchased from Cell Signaling Technology (1:1000 dilution). The 
antibody for Glut4 was purchased from Sigma Aldrich (1:1000 dilution). The 
antibody for CPT1A was purchased from Abcam (1:1000 dilution). The antibody 
for arginase 1 was purchased from Santa Cruz Biotechnology (1:250 dilution). 
Enzyme Linked Immunosorbent Assay. 
 Adipose tissue protein was isolated as described in the section 
above. ELISA was used to determine mg of analyte per mg of adipose tissue. All 
ELISA kits were purchased from R & D Systems and were performed following the 
manufacturer’s instructions.  
Histological Staining and Immunohistochemistry. 
 Adipose tissues were harvested, fixed in 4% paraformaldehyde, embedded 
into paraffin, and 7µm sections were cut and mounted on slides. Sections were 
either stained with Hematoxylin and Eosin for adipocyte size analysis using ImageJ 
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or stained for proteins of interest using immunohistochemistry. For 
immunohistochemistry, antigen retrieval was performed using citrate buffer with a 
pH of 6.0. Slides were then block in a solution of 10% goat serum, 1% BSA and 
an anti-CD16/32 fc block at a concentration of 10µg/mL for one hour. Primary 
antibodies were purchased from Abcam. Immunohistochemistry was visualized 
using an anti-rabbit polymer secondary antibody and chromogen solution 
purchased from Dako.  
Statistical Analysis. 
Data is presented as mean ± standard error of the mean. All statistical 
analyses were conducted using Prism software version 7 (GraphPad). Data sets 
comparing three or more groups were analyzed using a one-way ANOVA with 
Tukey’s multiple comparisons test. Data sets comparing two or more groups over 
time were analyzed using a two-way ANOVA with Tukey’s multiple comparisons 
test. P values less than 0.05 were considered significant.  
4.3. Results. 
Characterization of Resveratrol Scaffolds.  
Representative scanning electron microscopy images of resveratrol 
scaffolds are presented in Figure 4.1. Scaffolds were approximately 5mm in 
diameter and 2mm in height with pore sizes ranging from 250-500µm. The 
resveratrol content within the scaffolds was measured to be 103 ± 23 µg per 
scaffold. Each mouse received 2 scaffolds into each epididymal fat pad for a dose 
of 412 ± 92 µg per mouse. Unloaded scaffolds (referred to as “blank scaffolds” 
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from this point forward) were identical in dimensions and pore size with the only 
difference between the two scaffolds being resveratrol content. 
 
Mice Receiving Resveratrol Scaffold Implants Have Improved Glucose Tolerance 
when the High Fat Diet is removed.  
Mice were made obese and glucose intolerant through the feeding of a high 
fat diet (HFD). After two weeks, the fasting weight of mice on the HFD was 
significantly elevated from control mice kept on a normal chow diet (Supplemental 
Figure 4.8).  At this time point glucose tolerance was assessed using an 
intraperitoneal glucose tolerance test (IPGTT). Correlating with the significant 
increase in body weight gain, mice on the HFD had significant elevations in the 
area under the curve calculated from the IPGTT (Supplemental Figure 4.8B-C), 
indicating glucose intolerance. At this point, mice received either a blank or 
resveratrol scaffold. Additionally, a group of mice received the surgical procedure 
but no material implant (referred to as sham surgery from this point forward).  After 
administration of the scaffolds/surgeries, all groups were switched to a normal 
 
Figure 4.1. SEM Images of PLG scaffolds. Scanning electron microscope images of 
a (A) top and (B) side profile of a scaffold. Scaffolds are 5 mm in diameter, 2 mm in 
height, with a pore size ranging between 250 and 500 microns. Scale bar is 0.5 mm.  
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chow diet for two additional weeks. Fasting weight and glucose tolerance were 
assessed after two additional weeks. No difference in fasting weight was detected 
between treatment groups, however, both scaffold groups showed improvements 
in glucose tolerance during an IPGTT, with mice receiving resveratrol scaffolds 
significantly outperforming mice receiving sham surgery (Figure 4.2B-D). Taken 
together, the data demonstrates that mice receiving scaffold implants do not show 
differences in fasting weight but demonstrate improved glucose tolerance 
indicating accelerated recovery from HFD feeding.  
 
Figure 4.2. The effect of scaffold implant on glucose tolerance. (A) Outline of the 
study. (B) Fasting weight, (C) intraperitoneal glucose tolerance test and (D) area under 
the curve completed 2 weeks after scaffold implant and change to ND. Statistics were 
calculated using a one-way ANOVA with a Tukey’s multiple comparisons test. *p<0.05 
versus sham. For all conditions n=4-5 mice.  
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Mice Receiving Scaffold Implants Have Decreased Fat Pad Weight, Adipocyte 
Size, and Increased Lipid Metabolism.  
 In the high fat diet mouse model, the high lipid composition of the food 
results in rapid expansion of the adipose tissue in an attempt to store excess lipids 
 
Figure 4.3. The effect of scaffold implant on fat pad weight, adipocyte size, and 
lipid metabolism. (A-C) Representative images of formalin fixed paraffin embedded 
tissue sections stained with hematoxylin and eosin. Representative images of 
adipocytes from mice receiving (A) sham surgery, (B) blank scaffolds, and (C) 
resveratrol scaffolds 2 weeks after implant; scale bar is 100 µm. (D) Epididymal fat pad 
weights. (E) Quantification of average adipocyte area; n=3 mice per condition. (F) 
Representative western blots assessing ATGL and CPT1 in the epididymal fat two 
weeks after implant. Quantification of band intensity of (G) ATGL and (H) CPT1. For all 
conditions n=4 mice. Statistics were calculated using a one-way ANOVA with a Tukey’s 
multiple comparisons test.  *p<0.05 versus sham.  
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entering the body. When the adipose tissue is no longer able to keep up with the 
rapid influx of lipids cause by the diet, they accumulate in peripheral tissues 
resulting in glucose intolerance83. Therefore, we suspected the observed 
improvements in glucose tolerance might be attributed to increased lipid utilization 
in the adipose tissue caused by scaffold implants. In support of this, the weight of 
the epididymal adipose tissue of mice receiving scaffold implants was lower 
relative to sham surgery controls, with mice receiving blank scaffolds achieving 
statistical significance (Figure 4.3D). Because adipose tissue size is largely 
dictated by the cell’s lipid stores, we then assessed the average size of the 
adipocytes in the epididymal adipose tissue, using ImageJ analysis of adipose 
tissue sectioned stained with hematoxylin (Figure 4.3A-C). Interestingly, the 
average adipocyte size in epididymal fat pads implanted with both blank and 
resveratrol scaffolds was significantly lower relative mice receiving a sham surgery 
(Figure 4.3E). Finally, levels of ATGL, a marker of lipolysis, and CPT1, a marker 
of fatty acid oxidation was assessed at the implant site, however, no significant 
changes were detected at this time point (Figure 4.3F-H). Taken together this data 
suggests scaffold implant leads to a reduction in the size of the epididymal adipose 
tissue and this is achieved in part through a decrease in the lipid content within the 
adipocytes.  
Scaffold implant into the epididymal adipose tissue recruits’ cells expressing CPT1 
into the tissue.  
 Though western blot did not reveal any significant changes in CPT1 
expression, the decrease in adipocyte size suggests alterations in lipid metabolism 
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within the tissue are occurring. To better understand which cells types were 
responsible for these changes, we stained sections of the epididymal adipose 
tissue from each of our treatment groups for CPT1 using immunohistochemistry. 
Interestingly, the cells that showed the highest amount of CPT1 expression were 
not the adipocytes, but cells associated with the host located in an around the 
scaffold (Figure 4.4). Upon closer inspection, many of the cell types most heavily 
expressing CPT1 were the multinucleated giant cells that were in direct contact 
with the polymer. Overall this data suggests that scaffold implant recruits cells 
highly expressing CPT1, a marker of fatty acid oxidation to the adipose tissue, a 
tissue that is filled with fatty acids. These multinucleated giant cells could play a 
role in the ability of scaffolds to reduce adipocyte size and overall fat mass.  
Figure 4.4. Scaffold implant recruits’ cells expressing CPT1 to the epididymal 
adipose tissue. Representative images of immunohistochemistry staining for CPT1 in 
the epididymal adipose tissue in mice receiving a sham surgery, blank scaffold implant 
or resveratrol scaffold implant. Top three images are taken at 4x, scale bar represents 
500µm. Bottom three images are taken at 40x, scale bar represents 100µm. 
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Multinucleated giant cells expressing CPT1 also express anti-inflammatory 
macrophage markers.  
 It has been well documented that alternatively activated macrophages 
preferentially burn fatty acids as energy64. As multinucleated giant cells are the 
 
Figure 4.5. Multinucleated giant cells co-express anti-inflammatory markers 
arginase-1 and CD206. (A) Western blot assessing arginase-1 and CD206 levels in 
the epididymal adipose tissue 2 weeks after scaffold implant. Quantification of band 
intensity of (B) arginase-1 and (C) CD206. For all conditions n=4 mice. Statistics were 
calculated using a one-way ANOVA with a Tukey’s multiple comparisons test.  *p<0.05 
versus sham. †p<0.05 versus resveratrol scaffold. (D) Representative images of 
immunohistochemistry staining for arginase-1 and CD206 in the epididymal adipose 
tissue in mice receiving blank scaffold or resveratrol scaffold implants. Images are 
taken at 40x, scale bar represents 100µm. 
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result of a fusion of multiple macrophages, we sought to investigate their 
expression of anti-inflammatory macrophage markers arginase-1 and CD206 to 
support their use of fatty acids as energy. CD206 expression did not shown any 
significant changes between any of the groups (Figure 4.5A). However, western 
blot analysis revealed stark elevations in the anti-inflammatory marker arginase-1 
in both blank in resveratrol scaffolds with expression in blank scaffolds being 
significantly higher than their drug loaded counterparts. To better understand the 
cell types expressing these markers, immunohistochemistry staining for these 
markers was performed. Similar to the results of CPT1, the major cell population 
staining positive for CD206 and arginase-1 were the multinucleated giant cells 
directly interacting with the polymer scaffold matrix. Interestingly, giant cells in 
contact with the blank scaffold seemed to have higher expression of arginase-1 
relative to those in contact with resveratrol scaffolds. Taken together this data 
suggests that multinucleated giant cells that highly express CPT1 also express an 
anti-inflammatory immune cell profile further suggesting they are participating in 
lipid consumption within the adipose tissue.  
Mice Receiving Scaffold Implants Have Increased Expression of Proteins that 
Regulate Glucose Uptake in the Adipose Tissue. 
 A decrease in the area under the curve during an IPGTT suggests that 
implant of scaffolds could be altering glucose uptake. To test this hypothesis, 
glucose transport molecules were assessed at the implant site. In the adipose 
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tissue, glucose uptake is mainly facilitated by glucose transporter 4 (Glut4), which 
is responsible for insulin stimulated glucose transport113. Additionally, glucose can 
be taken up independent of insulin stimulation through glucose transporter 1 
(Glut1)46,48. Insulin dependent transport, measured through levels of 
phosphorylated Akt which promotes Glut4 expression after insulin binds to its 
receptor, and Glut4 expression, was unchanged between all groups (Figure 4.6C-
D). However, Glut1 was significantly elevated in the epididymal adipose tissue of 
mice receiving both blank and resveratrol scaffolds (Figure 4.6B). Taken together 
this data demonstrates that implant of scaffolds and not incorporation of 
resveratrol, results in the elevation of makers of insulin independent glucose 
 
Figure 4.6. Effect of scaffold implant on insulin signaling and glucose transport 
in the epididymal fat. (A) Western blot assessing Glut1, pAkt, and Glut4 levels in the 
epididymal adipose tissue 2 weeks after scaffold implant. Quantification of band 
intensity of (B) Glut1, (C) pAkt, and (D) Glut4. Statistics were calculated using a one-
way ANOVA with a Tukey’s multiple comparisons test; * indicates p<0.05 versus sham. 
For all conditions n=4 mice.  
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transport and this effect correlates with improved glucose tolerance measured 
during the intraperitoneal glucose tolerance test (Figure 4.2F-G).  
Immune cells recruited to the adipose tissue by scaffold implant show high levels 
of Glut1 expression. 
 To better understand the cell types responsible for elevated Glut1 within the 
adipose tissue, immunohistochemistry was used to stain for Glut1 within the 
implant site (Figure 4.7). Similar to CPT1, Glut1 was most expressed in the cells 
recruited to the adipose tissue by scaffold implant. The highest expression of Glut1 
was observed in the multinucleated giant cells that were in direct contact with the 
scaffold. Correlating with western blot analysis, no obvious differences in 
expression of Glut1 could be seen between blank and resveratrol scaffold groups. 
Taken together this data suggests that cellular infiltration into the adipose tissue 
 
Figure 4.7. Cells recruited to the adipose tissue by scaffold implant express high 
levels of Glut1. Representative images of immunohistochemistry staining for Glut1 in 
the epididymal adipose tissue in mice receiving a sham surgery, blank scaffold implant 
or resveratrol scaffold implant. Top three images are taken at 4x, scale bar represents 




due to scaffold implant is responsible the elevation of Glut1 expression within the 
tissue and this increase in glucose burning cells could represent a mechanism 
behind improved glucose tolerance observed during the IPGTT.  
4.4. Discussion. 
 The goal of this research was to investigate the ability of resveratrol loaded 
scaffolds to improve glucose tolerance and decrease fat mass when accompanied 
by a diet swap from a high fat diet to a normal diet. Two weeks after the initial 
feeding of the high fat diet, mice showed significant elevations in body weight and 
the area under the curve calculated from an intraperitoneal glucose tolerance test, 
indicating impaired glucose uptake in peripheral tissues at this time point. 
Supporting this data are previous studies demonstrating that the whole animal and 
importantly, the adipose tissue are dysregulated at this time point83.  
Implant of the scaffolds showed significant improvements in both adipose 
tissue weight and glucose tolerance relative to sham surgery controls. Additionally, 
the scaffold implant lead to a reduction in average adipocyte size which has been 
demonstrated to be correlated with healthy adipose tissue function114. When 
investigating the cells responsible for these changes we found that cells recruited 
to the epididymal fat by scaffold implant express high levels of CPT1, Glut1, 
Arginase 1, and CD206. Expression of these markers indication that these cells 
are anti-inflammatory and have a high appetite for both glucose and fatty acids.  
Based on this data, we propose that scaffolds recruit cells to the epididymal 
adipose tissue where due to the foreign body response. These cells require fuel in 
the form of both lipids and glucose to fuel their mechanisms to break down the 
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polymer matrix.  This increases the utilization of glucose and fatty acids in the 
adipose tissue and prevents ectopic accumulation of lipids in peripheral tissues 
such as the skeletal muscle and liver, saving insulin signaling in these tissues.  
4.5. Supplemental Data. 
 
  
Figure 4.8. Weight and glucose tolerance of mice after two weeks of HFD feeding. 
(A) Fasting weight, (B) intraperitoneal glucose tolerance test and (C) area under the 
curve assessed in mice after two weeks of high fat diet feeding. Statistics were 
calculated using an unpaired t-test; *p<0.05 versus vs HFD. For ND n=5 mice, for HFD 
n=15 mice. ND = normal diet and HFD = high fat diet 
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CHAPTER 5 
CONCLUDING REMARKS AND FUTURE DIRECTIONS 
5.1. Concluding Remarks 
Dysregulation of the adipose tissue provides a mechanistic link between the 
obese and type 2 diabetic disease states. With the number of individuals suffering 
from obesity associated type 2 diabetes ever rising, therapeutic platforms designed 
to specifically target, and correct adipose tissue dysfunction could prove to be 
promising at treating this large patient population. The primary objective of our 
work was to understand if delivery of therapeutic agents directly to the adipose 
tissue from biomaterial scaffolds, represents a promising platform to correct fat 
gain and glucose intolerance, two major concerns in the obese type 2 diabetic 
population.  
The first step towards accomplishing this objective focused on fully 
understanding the effects of our drug delivery vehicle, porous poly(lactide-co-
glycolide) scaffolds, on adipose tissue function, fat storage, and glucose uptake 
independent of drug loading (Chapter 2). This led to the novel discovery that the 
host response to poly(lactide-co-glycolide) scaffolds implanted into the adipose 
tissue decreased in tissue weight and fat content and elevated glucose uptake in 
tissue. Even more impactful was the ability to observe this effect on the systemic 
level through a decrease in fasting blood glucose. The polymer scaffolds were next 
tested in a mouse model of diet induced obesity and glucose intolerance. Implant 
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of scaffolds into the adipose tissue resulted in decreased fat mass not just 
in the site of implant but in distant fat depots, demonstrating an ability to influence 
fat storage at a global level. Additionally, the mice were protected from glucose 
intolerance. The ability of poly(lactide-co-glycolide) scaffolds to achieve the 
primary goals of reduced fat content and improved glucose tolerance independent 
of drug loaded clearly demonstrates potential as therapeutic devices to treat 
obesity associated type 2 diabetes.  
The next step towards achieving our objective was to attempt to augment 
the effects of the polymer scaffolds through the incorporation of resveratrol into the 
polymer matrix for direct delivery to the adipose tissue. This was accomplished by 
encapsulating resveratrol into the poly(lactide-co-glycolide) microparticles during 
the single emulsion step. Resveratrol was successfully incorporated into the 
scaffold and could be reproducibly loaded at similar concentrations. The ability of 
resveratrol loaded scaffolds to protect mice against glucose intolerance and fat 
gain was assessed using the same mouse model of diet induced obesity (Chapter 
3). Resveratrol loaded scaffolds showed improvement over blank scaffolds at 
preventing fat gain and improving glucose intolerance, significantly improving both 
metrics 5 weeks after administration. Additionally, resveratrol was still detected in 
the adipose tissue 5 weeks after implant, demonstrating the ability of scaffolds to 
release a drug payload for an extended period of time.  
Finally, the ability of resveratrol scaffold implants to combine with a change 
from a high fat diet to a normal diet, simulating a combination therapy with lifestyle 
changes, was investigated in Chapter 4. It was found that implant of resveratrol 
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loaded scaffolds into the adipose tissue resulted in the accelerated recovery from 
high fat diet feeding relative to control groups. Similar to previous studies these 
mice showed reduced fat content and improved glucose tolerance. Additionally, 
these studies led to the discovery that multinucleated cells that closely surround 
the polymer scaffold express high levels of markers for lipid metabolism and an 
anti-inflammatory phenotype. These cells could represent one of the mechanisms 
behind the protective effect of both resveratrol and blank scaffold implants.  
In summary, the novel contributions to the field can be summarized in three 
key points. Firstly, these studies demonstrate a protective effect of the host 
response to a polymer scaffold implanted into the adipose against a model of 
obesity associated type 2 diabetes, which has never before been reported. 
Secondly, this work reveals that implant of polymeric scaffolds into the adipose 
tissue has the ability to modulate glucose uptake to a degree where it can be 
detected on the systemic level. Finally, through the incorporation of small 
molecules into the polymer matrix of the scaffold, the therapeutic effects of these 
can be improved upon and combine well with lifestyle changes. Together this 
research forms the foundation of a new therapeutic platform for treatment of 
obesity associated type 2 diabetes. 
5.2. Future Directions 
The work outlined in this dissertation clearly demonstrates the therapeutic 
potential of using poly(lactide-co-glycolide) scaffolds implanted into the adipose 
tissue to treat obesity associated type 2 diabetes. Furthermore, the incorporation 
of resveratrol into the polymer matrix of the scaffold augments the effects beyond 
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the unloaded scaffold. However, despite this work demonstrating the promise of 
this approach, there is still room for improvement. Based on the knowledge gained 
thus far there are three areas in particular that will lead to the advancement of this 
therapeutic strategy. The first and likely largest obstacle is overcoming the 
invasiveness of the procedure required to implant the polymer scaffolds. Currently, 
the implant procedure requires the abdominal cavity to be opened and the incision 
required for the scaffold implant is large relative to the size of the animal. One path 
to reduce invasiveness would be for future studies to investigate if the protective 
effects observed in these studies can be reproduced when scaffolds are implanted 
into subcutaneous fat pads. This would allow for scaffolds to be delivered via a 
trocar needle, significantly reducing complications associated with the implant 
procedure. Alternatively, investigating if polymer particles could be an appropriate 
substitute for the scaffolds is another way to reduce invasiveness. The use of the 
microparticles would allow administration via injection, again significantly reducing 
the invasiveness of the procedure.  
The second method of improving scaffold-based delivery of therapeutics to 
the adipose tissue is to investigate ways to extend the release of the drug 
encapsulated within the polymer. While resveratrol was able to be successfully 
detected in the adipose tissue 5 weeks after implant, only 1% of the total 
resveratrol delivered remained at this timepoint. Importantly, when we investigated 
the amount of resveratrol remaining in the scaffold after the two-week timepoint, 
only 2% of the initial drug payload was detected in the adipose tissue, suggesting 
that there is a rapid release of the majority of the drug payload that occurs within 
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the first two weeks (and more likely the first few days) followed by an extended 
release of the remaining drug payload. Ideally, the drug would be released 
consistently over time. Ways to improve upon the release could lie in adjusting the 
porosity of the polymer. The pore size of the scaffolds used in these studies ranged 
from 250-500µm. This pore size was chosen so adipocytes which are on the order 
of 100µm could freely interact with the scaffold. However, the histological analysis 
revealed that immune cells, which are on the order of 10-20µm, and not adipocytes 
are in closest contact with the polymer. These cells function to break down the 
polymer leading to the accelerated release of the drug payload into the tissue as 
the polymer matrix is degraded. By reducing the pore size, it will take longer for 
the immune cells to penetrate into the scaffold which could result in a slower 
release of the drug payload.  
Finally, while the incorporation of resveratrol into the polymer matrix did 
show improvements in fat reduction and glucose tolerance relative to the unloaded 
polymer scaffolds, the impartments were modest. Resveratrol was selected for 
these studies due to the molecule’s promise in in-vivo animal models of obesity 
and the drawback of its rapid metabolism in the blood stream. However, resveratrol 
lacks potency. Investigating more potent drugs such as those already approved by 
the FDA for treating obesity and diabetes could prove to be a more fruitful endeavor 
than using natural compounds. Importantly, the techniques used in these studies 
to incorporate resveratrol into the polymer matrix of the scaffolds can be easily 
translated to a variety of compounds. The investigation of these avenues could 
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lead to the development of the next generation of polymer scaffolds for the 
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BEST PRACTICES FOR THE HIGH FAT DIET MOUSE MODEL OF 
DIET INDUCED OBESITY AND INSULIN RESISTANCE 
 
The high fat diet mouse model of diet induced obesity has been utilized for 
decades to study weight gain and glucose intolerance. There are several well 
written papers on the animal model the researcher should become familiar with 
before beginning a high fat diet animal study115–119. In addition, the following 
section will outline in detail the tips and recommendations for carrying out a high 
fat diet mouse study accumulated during my Ph.D. research.  
Ordering Mice. 
Mice should be ordered from the Jackson Laboratory. The mice used for 
these studies are male C57BL/6 mice. For the studies outlined in this dissertation, 
5-week-old mice were purchased. One drawback for choosing mice of this age is 
that they are still developing at this time period, which can complicate the 
interpretation of the results. Future studies should consider using mice 12 weeks 
or older to remove this additional variable as they are fully developed by this 
time120. Based on previous research, it is suggested that the housing density 
should be three mice per cage as it has been shown to reduce aggression121. It is 
important to consider the delivery schedule of the mice when planning a high fat 
diet animal study. Orders for mice from Jackson Laboratory must be placed with 
 96 
the Animal Resource Facility by Thursday at 2:00 pm. Mice then arrive the 
following Thursday exactly one week later.  
One-week acclimation period. 
  Upon arrival to the animal facility, mice will require a one-week acclimation 
period to adjust to their new environment. It is important that during this time the 
researcher does not handle the mice as it will increase the stress levels of the mice 
and could lead to aggressive behavior and poor data reproducibility in subsequent 
experiments. However, the one-week acclimation period should be used to ensure 
all materials needed for future sample and data collection are ordered and in the 
lab.  
One-week handling period. 
After the one-week acclimation period, the following week should be used 
to adjust mice to human handling. This period is essential to ensure that no 
unnecessary stress is placed on the mice when performing handling intensive 
procedures such as intraperitoneal glucose tolerance tests. During this week, the 
researcher should: 
1. Handle and scruff all mice daily. 
2. Label mice with ear punches to indicate number. 
3. Acquire baseline measurements of fasting weight and glucose.  
4. Acquire baseline DEXA and IPGTT measurements.  
It is recommended to take baseline DEXA scans prior to measurements of fasting 
weight, fasting glucose and the IPGTT. The reasoning for this is twofold. First, the 
total weight gain during high fat diet feeding is attributed mostly to an increase in 
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fat mass, which can account for 30-60% of the total body weight of high fat diet fed 
mice115. However, the majority of glucose uptake occurs in lean tissue such as the 
skeletal muscle and brain, therefore administering glucose during an IPGTT based 
on total body weight can result in disproportionally large glucose doses relative to 
glucose utilizing tissue. For this reason, it is recommended to administer glucose 
in proportion to lean mass measured by DEXA scans, requiring them to be 
completed prior to the IPGTT. Secondly, measuring weight, blood glucose, and the 
IPGTT all require fasting. The optimal fasting time for these measurements has 
been shown to be 6 hours because overnight fasts can result in muscle catabolism 
and 4 hour fasts do allow enough time for blood glucose levels to stabilize115. 
Multiple 6-hour fasts will put unnecessary stress on the mice and reduce overall 
food consumption hindering the progression of the diet, therefore, it is 
recommended that fasting measurements for body weight, blood glucose, and the 
IPGTT are completed on the same day allowing for one fast per week. Because 
DEXA scans are needed to calculate glucose dosage for the IPGTT, they should 
be completed before all fasting measurements.  
High fat diet feeding and acquisition of baseline measurements.  
 It has been well established that one week of high fat diet feeding results in 
significant increases in fat mass and insulin resistance83. Because the goals of the 
research in this dissertation were focused around treating these two conditions, 
only one week of high fat diet feeding was completed prior to administering 
treatments. However, should future studies aim to address conditions such as 
inflammation or hyperinsulinemia, it will be necessary to keep the mice on the high 
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fat diet for longer periods of time (~8 weeks) to allow these conditions to occur122. 
One important consideration for beginning the high fat diet stage of the animal 
study is that the mouse cages should be changed out upon the switch from the 
normal diet to the high fat diet. Mice are known to hide their food in the bedding of 
their cage therefore changing out the cages ensures that the mice will only have 
access to the high fat diet allowing the effects of the model to begin immediately.  
Tips for Performing the Intraperitoneal Glucose Tolerance Test. 
During the intraperitoneal glucose tolerance test, mice are fasted for 6-
hours before receiving injections of D-glucose into the peritoneal cavity. It is critical 
to place mice in a clean cage during the fasting period of this procedure. As 
mentioned above, mice are prone to hiding food in their bedding. Failing to place 
the mice in a new cage would still allow access to this food and could prevent blood 
glucose measurements from being collected during the fasted state. Blood glucose 
measurements are collected via the end of the tail. Collecting blood from this site 
requires the tip of the tail to be removed using a sterile razor. It was found that 
removing approximately 2mm off the end of the tail is optimal for this procedure, 
allowing for easy blood collection throughout the experiment while minimizing the 
stress on the mouse. Because removing the end of the tail places stress on the 
mouse, which can lead to aggression and inconsistent blood glucose 
measurements, it is recommended to allow mice to rest in the cage for a minimum 
of 30 minutes after the end of the tail is removed. Glucose is then administered 
normalized to the lean mass (2g glucose per kg of lean mass). Blood samples are 
collected at 0, 15, 30, 60, 90, and 120 minutes after glucose administration. 
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Because measurements are time sensitive it is not recommended that a 
researcher complete this task alone, as collecting and recording glucose 
measurements from many mice is time intensive. At minimum there should be two 
researchers, one collecting the glucose measurements and one recording them.   
Additional Considerations for performing a High Fat Diet Animal Study. 
 There are two animal facilities utilized for the lab’s animal studies: The 
Discovery animal facility and the Graduate Student Resource Center (GSRC) 
animal facility. DEXA scans are performed at the Discovery animal facility, 
however, this facility has issues keeping the 12-hour light and dark cycles. 
Specifically, there have been instances when lights in a room are kept on for 24 
hours. As mice are nocturnal, the failure of a proper dark cycle causes additional 
stress and has resulted in difficulty in obtaining reproducible blood glucose 
measurements. Therefore, if possible, it is recommended that mice kept at 
Discovery are only used for body composition measurements. Additionally, 
keeping mice in rooms that are heavily utilized will allow for problems to be 
identified and resolved more efficiently.  
For both the Discovery and GSRC facilities, it is beneficial to keep an open 
dialogue with the animal facility staff. Animal facility staff is responsible for ensuring 
mice are well fed and cages are changed weekly. However, the researcher is 
responsible for administering the high fat diet. If food levels run low, the staff will 
be forced to give the mice normal chow to keep them healthy. A change in diet will 
prevent any data from being properly interpreted and essentially ruin the 
experiment. To prevent this, fresh food should be given to the mice once a week 
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at minimum. It was found that approximately 150g of food will be sufficient to feed 
three mice for a week. In the event that food stores run low, requesting that the 




BEST PRACTICES FOR THE FABRICATION OF POLY(LACTIDE-
CO-GLYCOLIDE) SCAFFOLDS 
 
 Fabricating scaffolds for implant into mice requires forethought and 
planning to ensure scaffolds are completely leached and properly analyzed prior 
to the time of surgical implant. Additionally, over the course of my doctoral research 
there has been many challenges in fabricating reproducible scaffolds. This section 
will outline tips and recommendations for the scaffold fabrication process.  
 The first, and most important, consideration when fabricating scaffolds is 
humidity. We found that fabricating scaffolds during humid conditions lead to poor 
coating of the polymer particles around the salt crystals. This leads to the 
fabrication of inconsistent scaffolds (and drug loading if the polymer contains a 
therapeutic agent) and should be avoided. To solve this issue, a dehumidifier and 
humidity monitoring system has been placed in the room where scaffolds are 
fabricated. The dehumidifier should be turned on 24 hours prior to scaffold 
fabrication. However, the dehumidifier cannot properly lower the humidity of the 
room with the air conditioning unit on and cycling fresh humid air into the room, 
therefore the air conditioning unit must be turned off prior and during the scaffold 
fabrication process. It was found that lowering the humidity in the scaffold 
fabrication room to below 40% is adequate for scaffold fabrication.  
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The second major consideration when fabricating scaffolds is the leaching 
process. To remove the salt crystals after the gas foaming process, scaffolds are 
leached in deionized water. It is important to ensure all salt is removed from the 
scaffolds prior to implant into the adipose tissue. Salt removal is assessed by the 
weight of the scaffolds. However, to gain an accurate measurement of scaffold 
weight, they must be completely dried of all water, which takes a minimum of 24 
hours when placed in a desiccator. Multiple leaching and drying cycles are 
necessary to determine if the salt is completely removed from the polymer matrix; 
therefore, scaffolds should be fabricated weeks before the date of the surgery. 
Additionally, it was found that the incorporation of resveratrol into the polymer 
matrix increased the number of leaching cycles needed to completely remove the 
salt crystals. A possible explanation is the incorporation of resveratrol increased 
the overall hydrophobicity of the scaffold, increasing the time required for the water 
to permeate thorough the scaffold and remove the salt. Based on this, it would be 
wise to assess the leaching time for scaffolds containing new small molecules well 
before they are needed for animal studies.  
Originally, scaffolds were fabricated individually. This process involved 
weighing out the polymer and salt required to make one scaffold into an Eppendorf 
tube and mixing the contents of each tube manually with a small drill bit.  Not only 
was this method time intensive, requiring the precise weighing of small masses 
(2.5mg of polymer and 75mg of salt), but the scaffolds produced from this method 
had lower than expected weights with high variability. The variation in weight was 
due to inconsistent coating of the polymer around the salt crystals as the quality of 
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mixing changed between each scaffold. To overcome this issue, a new fabrication 
technique was developed to allow scaffolds to be made in “batches.” For this 
method, material for multiple scaffolds is weighed into a single 2mL Eppendorf 
tube. The polymer and salt are then mixed by inverting the tube several times over 
the course of five minutes. Next, enough pre-mixed polymer and salt for a single 
scaffold (77.5mg) is weighed out and the scaffold fabrication procedure is 
completed. Scaffolds made using this method were found to have better coating, 
reflected by higher average weights, and lower variability. One important 
consideration is to weigh out enough polymer for 2 more scaffolds than desired. 
Some polymer and salt are lost during the weighing process, weighing out material 
for 2 additional scaffolds will account for this loss.  
